[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Beevers Manufacturing & Supply, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":283},{"warningLetters":4,"total":282},[5,32,55,75,96,115,136,154,172,193,210,229,248,266],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},429,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-12-09T05:00:00Z\">12\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-12T05:00:00Z\">11\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdevere-manufacturing-inc-715846-11122025\">DeVere Manufacturing Inc. \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-16\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Randy D. Stevenson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DeVere Manufacturing Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1923 Beloit Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Janesville\u003C\u002Fspan>, \u003Cspan>WI\u003C\u002Fspan> \u003Cspan>53546\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rstevenson@deverechemical.com\"> rstevenson@deverechemical.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-26-16\u003C\u002Fp>\u003Cp>November 12, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Stevenson:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug product manufacturing facility, DeVere Manufacturing Inc., FEI 3012088459, at 1923 Beloit Ave., Janesville, WI, from June 2 to 4, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your June 20, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture over-the-counter (OTC) drug products, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Hand Sanitizer Foam, both alcohol and alcohol-free formulas, using the same equipment that you use to manufacture non-drug products, including industrial cleaning detergents and disinfectants such as Bowl Cleaner, a strongly acidic (pH &lt;2) toilet cleaner, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your response, you commit to maintaining cleaning records for all shared equipment and performing additional cleaning validation. However, your response is inadequate. Under CGMP, it is unacceptable to manufacture drug products using the same equipment you use to manufacture non-pharmaceutical products due to the risk of cross-contamination. Inadequate removal of active ingredients and product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\u003C\u002Fp>\u003Cp>Further, we acknowledge your commitment in your August 4, 2025, response to cease production of all benzalkonium chloride-containing drug products at this facility for the U.S. market. We acknowledge your intent to delist your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product line by September 30, 2025.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Confirmation of whether you will discontinue manufacturing drug products on shared equipment in your facility and implement appropriate controls to prevent cross-contamination.\u003C\u002Fli>\u003Cli>If you intend to continue to manufacture both pharmaceutical and non-pharmaceutical products at your facility, provide a plan to show how you will maintain appropriate separation with dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\u003C\u002Fli>\u003Cli>Provide a risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning procedures with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to conduct adequate finished product release testing for each batch of your hand sanitizer drug products, including but not limited to, testing of the identity and strength of each active ingredient, testing for impurities, and testing for objectionable microorganisms. You provided records demonstrating that you test your hand sanitizer drug products for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your records also demonstrate titration, for determination of quaternary ammonium cations in the benzalkonium chloride hand sanitizers. However, in the past two years, you manufactured more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of hand sanitizer using \u003Cstrong>(b)(4)\u003C\u002Fstrong> water, which is unsuitable for use as a component of a drug product. You did not perform microbiological testing on those batches made with unsuitable water.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide sufficient details of the test methods and specifications you intend to implement for your OTC drug products to ensure your finished products meet appropriate standards prior to release and distribution.\u003C\u002Fp>\u003Cp>Full release testing, including strength and identity testing of the active ingredient and appropriate microbiological testing, must be performed before drug product release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to perform adequate identity testing on each shipment of each lot of incoming components (e.g., benzalkonium chloride, ethanol, glycerin) used in the manufacture of your OTC drug products. In addition, you relied on your suppliers’ certificate of analysis without establishing the reliability of each of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>Identity testing for high-risk drug components ethanol and glycerin include a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for methanol or diethylene glycol (DEG) or ethylene glycol (EG) levels, respectively. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>\u003Cem>Ethanol\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test each shipment of each lot of ethanol, used as an active pharmaceutical ingredient, for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fpolicy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol.\u003C\u002Fp>\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test each shipment of each lot of glycerin, used as an inactive ingredient, for DEG or EG contamination.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-propylene-glycol-maltitol-solution-hydrogenated-starch-hydrolysate-sorbitol.\u003C\u002Fp>\u003Cp>In your response, you commit to full USP compendial testing of raw materials from your vendors, including methanol testing for ethanol and DEG\u002FEG for glycerin. Your response is inadequate. You failed to specify the timing for implementation of testing and how you intend to sample and monitor incoming materials. Further, you did not evaluate previously distributed drug products or describe how suppliers will be qualified.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have appropriate assurance that components conform to appropriate specifications prior to use in the drug products you manufacture. As a manufacturer, you have the responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B and C of the United States Pharmacopeia (USP) monograph.\u003C\u002Fli>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to exercise its responsibility to adequately review production records prior to approval (e.g., failed to investigate out-of-specification test results, reprocessing, and errant label reconciliation) and failed to establish and follow written procedures (e.g., annual product reviews, complaints, recalls, CGMP training, process validations, analytical method validation).\u003C\u002Fp>\u003Cp>Additionally, your QU failed exercise its responsibility to ensure that your component water is suitable for its intended use. Our inspection documented that you used “\u003Cstrong>(b)(4)\u003C\u002Fstrong> water” (also referred to as “\u003Cstrong>(b)(4)\u003C\u002Fstrong> water” in your batch records) as the main component of manufacturing OTC hand sanitizers. Although your OTC product labels identify purified water as the first inactive ingredient, your QU does not ensure that purified water is used in the product formulation.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations. For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the new system consistently produces water adhering to Purified Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> water on the quality of all drug product lots currently in U.S. distribution and within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a previous inspection dated January 26 to February 2, 2018, FDA cited similar CGMP violations for the failure of the quality unit to adequately exercise its responsibilities. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug product manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012088459 and ATTN: Kara S. Quinn.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nReference #:\n\n320-26-16\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Randy D. Stevenson\n\nRecipient Title\n\nPresident\n\nDeVere Manufacturing Inc.\n\n1923 Beloit Avenue\n\nJanesville, WI 53546\n\nUnited States\n\nrstevenson@deverechemical.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-16\nNovember 12, 2025\nDear Mr. Stevenson:\nThe United States Food and Drug Administration (FDA) inspected your drug product manufacturing facility, DeVere Manufacturing Inc., FEI 3012088459, at 1923 Beloit Ave., Janesville, WI, from June 2 to 4, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your June 20, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\nYou manufacture over-the-counter (OTC) drug products, (b)(4) Hand Sanitizer Foam, both alcohol and alcohol-free formulas, using the same equipment that you use to manufacture non-drug products, including industrial cleaning detergents and disinfectants such as Bowl Cleaner, a strongly acidic (pH \u003C2) toilet cleaner, and (b)(4).\nIn your response, you commit to maintaining cleaning records for all shared equipment and performing additional cleaning validation. However, your response is inadequate. Under CGMP, it is unacceptable to manufacture drug products using the same equipment you use to manufacture non-pharmaceutical products due to the risk of cross-contamination. Inadequate removal of active ingredients and product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\nFurther, we acknowledge your commitment in your August 4, 2025, response to cease production of all benzalkonium chloride-containing drug products at this facility for the U.S. market. We acknowledge your intent to delist your (b)(4) product line by September 30, 2025.\nIn response to this letter, provide:\nConfirmation of whether you will discontinue manufacturing drug products on shared equipment in your facility and implement appropriate controls to prevent cross-contamination.\nIf you intend to continue to manufacture both pharmaceutical and non-pharmaceutical products at your facility, provide a plan to show how you will maintain appropriate separation with dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\nProvide a risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\nAppropriate improvements to your cleaning procedures with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).\nYou failed to conduct adequate finished product release testing for each batch of your hand sanitizer drug products, including but not limited to, testing of the identity and strength of each active ingredient, testing for impurities, and testing for objectionable microorganisms. You provided records demonstrating that you test your hand sanitizer drug products for (b)(4). Your records also demonstrate titration, for determination of quaternary ammonium cations in the benzalkonium chloride hand sanitizers. However, in the past two years, you manufactured more than (b)(4) batches of hand sanitizer using (b)(4) water, which is unsuitable for use as a component of a drug product. You did not perform microbiological testing on those batches made with unsuitable water.\nYour response is inadequate. You did not provide sufficient details of the test methods and specifications you intend to implement for your OTC drug products to ensure your finished products meet appropriate standards prior to release and distribution.\nFull release testing, including strength and identity testing of the active ingredient and appropriate microbiological testing, must be performed before drug product release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n3. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou failed to perform adequate identity testing on each shipment of each lot of incoming components (e.g., benzalkonium chloride, ethanol, glycerin) used in the manufacture of your OTC drug products. In addition, you relied on your suppliers’ certificate of analysis without establishing the reliability of each of your component suppliers’ test analyses at appropriate intervals.\nIdentity testing for high-risk drug components ethanol and glycerin include a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for methanol or diethylene glycol (DEG) or ethylene glycol (EG) levels, respectively. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nEthanol\nYou failed to adequately test each shipment of each lot of ethanol, used as an active pharmaceutical ingredient, for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fpolicy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol.\nGlycerin\nYou failed to adequately test each shipment of each lot of glycerin, used as an inactive ingredient, for DEG or EG contamination.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-propylene-glycol-maltitol-solution-hydrogenated-starch-hydrolysate-sorbitol.\nIn your response, you commit to full USP compendial testing of raw materials from your vendors, including methanol testing for ethanol and DEG\u002FEG for glycerin. Your response is inadequate. You failed to specify the timing for implementation of testing and how you intend to sample and monitor incoming materials. Further, you did not evaluate previously distributed drug products or describe how suppliers will be qualified.\nWithout adequate testing, you do not have appropriate assurance that components conform to appropriate specifications prior to use in the drug products you manufacture. As a manufacturer, you have the responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\nIn response to this letter, provide:\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B and C of the United States Pharmacopeia (USP) monograph.\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nThe chemical and microbiological quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) failed to exercise its responsibility to adequately review production records prior to approval (e.g., failed to investigate out-of-specification test results, reprocessing, and errant label reconciliation) and failed to establish and follow written procedures (e.g., annual product reviews, complaints, recalls, CGMP training, process validations, analytical method validation).\nAdditionally, your QU failed exercise its responsibility to ensure that your component water is suitable for its intended use. Our inspection documented that you used “(b)(4) water” (also referred to as “(b)(4) water” in your batch records) as the main component of manufacturing OTC hand sanitizers. Although your OTC product labels identify purified water as the first inactive ingredient, your QU does not ensure that purified water is used in the product formulation.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations. For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the new system consistently produces water adhering to Purified Water, USP monograph specifications and appropriate microbial limits.\nA detailed risk assessment addressing the potential effects of the use of (b)(4) water on the quality of all drug product lots currently in U.S. distribution and within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nRepeat Violations at Facility\nIn a previous inspection dated January 26 to February 2, 2018, FDA cited similar CGMP violations for the failure of the quality unit to adequately exercise its responsibilities. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug product manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012088459 and ATTN: Kara S. Quinn.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","DeVere Manufacturing Inc.","devere-manufacturing-inc-715846-11122025","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdevere-manufacturing-inc-715846-11122025","2026-10-26T08:08:23.707133+00:00","Warning Letter","Issued","2025-12-09","715846","Drugs","Mr. Randy D. Stevenson","2026-08-19T11:13:49.342+00:00","Via Electronic Mail - Return Receipt Requested","320-26-16","2025-11-12",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":50,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":19,"reference_number":19,"action_taken_date":54,"medical_device_id":19,"response_letter_date":19},2213,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2023-02-07T14:20:00Z\">02\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-13T05:00:00Z\">12\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquality-supplement-manufacturing-inc-637182-12132022\">Quality Supplement Manufacturing, Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations III ","CGMP\u002FManufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Raymundo Osuna\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President of Operations\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Quality Supplement Manufacturing, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>300 N. Macarthur Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Oklahoma City\u003C\u002Fspan>, \u003Cspan>OK\u003C\u002Fspan> \u003Cspan>73127\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations III \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 13, 2022\u003Cbr>\n\u003Cbr>\nRE: 637182\u003C\u002Fp>\n\n\u003Cp>Dear Raymundo Osuna,\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 300 N. Macarthur Blvd, Oklahoma City, Oklahoma, from June 7, 2022, through June 13, 2022. Based on inspectional findings and a review of your product labels, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>We received your written response, dated July 5, 2022, to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. We have reviewed that document and our comments are listed following each of the significant violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). Based on the inspection, we determined that your products, including your&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>The significant violations documented during the inspection include, but are not limited to the following:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish product specifications for the identity and purity of the finished batch of the dietary supplement as required by 21 CFR 111.70(e). Specifically, you told our investigator that you have created finished product specifications for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>products; however, these specifications fail to include established specifications for the identity and purity of each of the products.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your response, which states, “Raw materials and finished product shall be tested for identity, purity, or composition as stated in the revised SOP…The Quality Department will be working with the labs to establish specifications for identity, purity, and composition for finished products.” However, we are unable to evaluate the adequacy of your corrective action because you did not provide finished product specifications for our review.\u003C\u002Fp>\n\n\u003Cp>2. You failed to prepare and follow a written master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Specifically, you provided MMRs for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also provided batch production records (BPR) for two lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and two lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. With the exception of one lot of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, none of the BPRs matched the MMRs for the products. As such, the BPRs do not support that you are preparing and following written MMRs for each unique formulation and batch size of dietary supplement that you manufacture. In preparing the MMRs, they must include the required elements of 21 CFR 111.210.\u003C\u002Fp>\n\n\u003Cp>We reviewed your response in which you state, “Quality Supplement Manufacturing will have the SOP revised and implement the new process in place within the next 90 days.” We are unable to evaluate the adequacy of your corrective action because you did not provide any MMRs for any manufactured dietary supplement for our review.\u003C\u002Fp>\n\n\u003Cp>3. You failed to verify, for a subset of finished dietary supplement batches that you identify through a sound statistical sampling plan (or for every finished batch), that your finished batch of the dietary supplement meets product specifications for identity, purity, strength, and composition, as required by 21 CFR 111.75(c). Specifically, your firm’s BPRs for the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) indicate that the supplement products contain multiple dietary ingredients; however, during inspection, you stated that you verify the strength for only one dietary ingredient in each of the dietary supplements. Selecting only one of multiple dietary ingredients in the supplement products does not verify your production and process control system is producing a dietary supplement that meets the required product specifications for identity, purity, strength, and composition of the dietary supplement.\u003C\u002Fp>\n\n\u003Cp>We reviewed your response in which you state, “Quality Supplement Manufacturing will have the SOP revised and implement the new process in place within the next 90 days.” We are unable to evaluate the adequacy of your corrective action because you did not provide any standard operating procedures for review.\u003C\u002Fp>\n\n\u003Cp>4. You failed to ensure all tests and examinations that are used to determine whether a specification is met are appropriate and scientifically valid in accordance with 21 CFR 111.75(h)(1). Specifically, you stated “the only analysis for the finished product is by input and a \u003Cstrong>(b)(4)\u003C\u002Fstrong> test.” The input of the various dietary ingredients during production and subsequent analysis of a single dietary ingredient alone in the finished product is not sufficient to verify specifications for identity, purity, strength, and composition in a finished product because inputting specific amounts of various ingredients during manufacturing does not ensure that specifications are met in the finished product, nor does later testing for a single dietary ingredient assess any other components within the finished product.\u003C\u002Fp>\n\n\u003Cp>5. Your quality control personnel did not reject a component and dietary supplement for which a specification was not met, as required by 21 CFR 111.77(a), nor did they approve a treatment, an in-process adjustment, or reprocessing that would ensure the quality of the finished dietary supplement and that the dietary supplement would be packaged and labeled as specified in the MMR. You have in-process specifications within your MMR for fill weights of capsules and tablets to ensure that the finished product meets the label declarations. In several instances, your product neither met these specifications nor were they approved for an appropriate treatment, in-process adjustment, or reprocessing. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o The tablet run sheet for \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>(lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes out of specification fill weights. The BPR states the fill weight range is \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg. The tablet run sheet has weights throughout in the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> range and notes “tablet won’t hit the weight so running \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” A corrective action approved by the firm’s quality unit was not documented.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o The capsule run sheet for \u003Cstrong>(b)(4)\u003C\u002Fstrong> (lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes out of specification fill weights. The BPR states the fill weight range as&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> mg. The QC capsule run sheet has fill weights listed at \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg, \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg, \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg and \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg. There are several notes that adjustments are being made but no corrective action approved by the firm’s quality unit addresses the underweight capsules.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response in which you state that the root cause for the out of specification fill weights for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product was “lack of training” and that you would be “revising your sample run process” along with “[a] new SOP…to explain the sample run process and how to run deviations.” We are unable to evaluate the adequacy of your corrective action because you did not provide any training records for review, new SOPs, or other documentation on your new sample run or deviation process.\u003C\u002Fp>\n\n\u003Cp>6. Your quality control personnel failed to reject the component, dietary supplement, package, or label, when a specification established in accordance with 21 CFR 111.70 is not met, nor did they approve a permitted treatment, an in-process adjustment, or reprocessing, as required by 21 CFR 111.113(b)(2). For example, your finished product test for your \u003Cstrong>(b)(4)\u003C\u002Fstrong>(lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes strength analysis for the dietary ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The product specification for the ingredient in the supplement products is \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002Ftablet. An out of specification result of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002Ftablet was reported by your contract lab \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A corrective action approved by the firm’s quality unit was not documented.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response in which you state that “[the] Quality Department will be signing off on all finished product test results.” We are unable to evaluate the adequacy of your corrective action because you did not provide any test result records or other documentation to show the implementation of the new procedure.\u003C\u002Fp>\n\n\u003Cp>7. Your quality control operations for the MMR, the BPR, and manufacturing operations failed to include approving or rejecting any reprocessing, as required by 21 CFR 111.123(a)(5). For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> barrels of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets (lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) were returned to the blending stage for grinding; however, the BPR does not include documentation showing that your quality control operations approved or rejected any reprocessing.\u003C\u002Fp>\n\n\u003Cp>8. Your quality control failed to document in the BPR at the time of performance the approval and release, or the rejection of a batch of dietary supplement for distribution, as required by 21 CFR 111.260(l)(3). For example, BPRs for&nbsp;&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) do not include documentation that your quality control personnel approved and released, or rejected, the batches for distribution.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, even if your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product was not an unapproved new and misbranded drug, this product and others would be misbranded under section 403 of the Act because it does not comply with the labeling requirements for dietary supplements.\u003Cbr>\nSpecifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary supplement products are misbranded under section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling for your products does not comply with the labeling requirements for dietary supplements in 21 CFR 101.36. For example,\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Facts label fails to declare the source of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. (21 CFR 101.36(d))\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Facts label incorrectly declares as a (b)(2)-dietary ingredient, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. 21 CFR 101.9(c)(8)(iv) lists an RDI for&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mcg based on the AI (adequate intake) that pertains only to&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> should be listed as a (b)(3)-dietary ingredient.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product fails to declare the source of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as indicated in the master manufacturing record; e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> (as \u003Cstrong>(b)(4)\u003C\u002Fstrong>). (21 CFR 101.36(d))\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> fails to express the metric quantitative amounts by weight per serving of other dietary ingredients in accordance with 21 CFR 101.36(b)(3)(ii)(A); for example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg should be&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>g.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> fails to declare the quantitative amount of \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the % Daily Value based upon the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the product formula, as required by 21 CFR 101.36(b)(2)\u003C\u002Fp>\n\n\u003Cp>2. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product is misbranded within the meaning of section 403(w)(2) of the Act [21 U.S.C. § 343(w)(2)], in that the finished product labels fail to declare the major food allergen, shrimp and crab, as required by section 403(w)(1) of the Act. Specifically, as you have chosen to use a “Contains” statement, you must declare the specific type of Crustacean shellfish.\u003C\u002Fp>\n\n\u003Cp>3. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> products are each misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that each product label fails to declare the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically,\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Facts label declares the \u003Cstrong>(b)(4)\u003C\u002Fstrong> but fails to state the standardized common name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” as listed in the reference Herbs of Commerce, as incorporated by 21 CFR 101.4(h).\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product’s ingredient list declares “flavorless coating (Yellow 5, Red 40, Blue 1)” which is not the common or usual name of an ingredient. Furthermore, your batch production records for the product indicate “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” as an ingredient but this ingredient does not appear in the ingredient list of your product label.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Facts label declares the \u003Cstrong>(b)(4)\u003C\u002Fstrong> but fails to state the standardized common name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” as listed in Herbs of Commerce. [See 21 CFR 101.4(h)] Furthermore, the source ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> fails to be listed first within the parentheses, and then followed by the \u003Cstrong>(b)(4)\u003C\u002Fstrong> name within parentheses; for example, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>4. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product label is misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761 of the Act) may receive a report of a serious adverse event with such dietary supplement.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at the following email: dana.lewis@fda.hhs.gov (preferred), or you may mail a hard copy, addressed to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any further questions, please contact me at 214-253-5205 or by email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Edmundo Garcia\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food West, Division 3\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nRaymundo Osuna\n\nRecipient Title\n\nVice President of Operations\n\nQuality Supplement Manufacturing, Inc.\n\n300 N. Macarthur Blvd\n\nOklahoma City, OK 73127\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nWARNING LETTER\n\nDecember 13, 2022\n\nRE: 637182\n\nDear Raymundo Osuna,\n\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 300 N. Macarthur Blvd, Oklahoma City, Oklahoma, from June 7, 2022, through June 13, 2022. Based on inspectional findings and a review of your product labels, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at www.fda.gov.\n\nWe received your written response, dated July 5, 2022, to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. We have reviewed that document and our comments are listed following each of the significant violations.\n\nAdulterated Dietary Supplements\n\nThe inspection of your facility revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). Based on the inspection, we determined that your products, including your (b)(4), and (b)(4) products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\n\nThe significant violations documented during the inspection include, but are not limited to the following:\n\n1. You failed to establish product specifications for the identity and purity of the finished batch of the dietary supplement as required by 21 CFR 111.70(e). Specifically, you told our investigator that you have created finished product specifications for your (b)(4) and (b)(4) products; however, these specifications fail to include established specifications for the identity and purity of each of the products.\n\nWe acknowledge your response, which states, “Raw materials and finished product shall be tested for identity, purity, or composition as stated in the revised SOP…The Quality Department will be working with the labs to establish specifications for identity, purity, and composition for finished products.” However, we are unable to evaluate the adequacy of your corrective action because you did not provide finished product specifications for our review.\n\n2. You failed to prepare and follow a written master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Specifically, you provided MMRs for the (b)(4) and (b)(4). You also provided batch production records (BPR) for two lots of (b)(4) and two lots of (b)(4). With the exception of one lot of the (b)(4), none of the BPRs matched the MMRs for the products. As such, the BPRs do not support that you are preparing and following written MMRs for each unique formulation and batch size of dietary supplement that you manufacture. In preparing the MMRs, they must include the required elements of 21 CFR 111.210.\n\nWe reviewed your response in which you state, “Quality Supplement Manufacturing will have the SOP revised and implement the new process in place within the next 90 days.” We are unable to evaluate the adequacy of your corrective action because you did not provide any MMRs for any manufactured dietary supplement for our review.\n\n3. You failed to verify, for a subset of finished dietary supplement batches that you identify through a sound statistical sampling plan (or for every finished batch), that your finished batch of the dietary supplement meets product specifications for identity, purity, strength, and composition, as required by 21 CFR 111.75(c). Specifically, your firm’s BPRs for the (b)(4) (lots (b)(4) and (b)(4)) and (b)(4) (lots (b)(4) and (b)(4)) indicate that the supplement products contain multiple dietary ingredients; however, during inspection, you stated that you verify the strength for only one dietary ingredient in each of the dietary supplements. Selecting only one of multiple dietary ingredients in the supplement products does not verify your production and process control system is producing a dietary supplement that meets the required product specifications for identity, purity, strength, and composition of the dietary supplement.\n\nWe reviewed your response in which you state, “Quality Supplement Manufacturing will have the SOP revised and implement the new process in place within the next 90 days.” We are unable to evaluate the adequacy of your corrective action because you did not provide any standard operating procedures for review.\n\n4. You failed to ensure all tests and examinations that are used to determine whether a specification is met are appropriate and scientifically valid in accordance with 21 CFR 111.75(h)(1). Specifically, you stated “the only analysis for the finished product is by input and a (b)(4) test.” The input of the various dietary ingredients during production and subsequent analysis of a single dietary ingredient alone in the finished product is not sufficient to verify specifications for identity, purity, strength, and composition in a finished product because inputting specific amounts of various ingredients during manufacturing does not ensure that specifications are met in the finished product, nor does later testing for a single dietary ingredient assess any other components within the finished product.\n\n5. Your quality control personnel did not reject a component and dietary supplement for which a specification was not met, as required by 21 CFR 111.77(a), nor did they approve a treatment, an in-process adjustment, or reprocessing that would ensure the quality of the finished dietary supplement and that the dietary supplement would be packaged and labeled as specified in the MMR. You have in-process specifications within your MMR for fill weights of capsules and tablets to ensure that the finished product meets the label declarations. In several instances, your product neither met these specifications nor were they approved for an appropriate treatment, in-process adjustment, or reprocessing. For example:\n\no The tablet run sheet for (b)(4) (lot (b)(4)) includes out of specification fill weights. The BPR states the fill weight range is (b)(4) mg. The tablet run sheet has weights throughout in the (b)(4) range and notes “tablet won’t hit the weight so running (b)(4).” A corrective action approved by the firm’s quality unit was not documented.\n\no The capsule run sheet for (b)(4) (lot (b)(4)) includes out of specification fill weights. The BPR states the fill weight range as (b)(4) mg. The QC capsule run sheet has fill weights listed at (b)(4) mg, (b)(4) mg, (b)(4) mg and (b)(4) mg. There are several notes that adjustments are being made but no corrective action approved by the firm’s quality unit addresses the underweight capsules.\n\nWe have reviewed your written response in which you state that the root cause for the out of specification fill weights for your (b)(4) product was “lack of training” and that you would be “revising your sample run process” along with “[a] new SOP…to explain the sample run process and how to run deviations.” We are unable to evaluate the adequacy of your corrective action because you did not provide any training records for review, new SOPs, or other documentation on your new sample run or deviation process.\n\n6. Your quality control personnel failed to reject the component, dietary supplement, package, or label, when a specification established in accordance with 21 CFR 111.70 is not met, nor did they approve a permitted treatment, an in-process adjustment, or reprocessing, as required by 21 CFR 111.113(b)(2). For example, your finished product test for your (b)(4)(lot (b)(4)) includes strength analysis for the dietary ingredient (b)(4). The product specification for the ingredient in the supplement products is (b)(4) mg\u002Ftablet. An out of specification result of (b)(4) mg\u002Ftablet was reported by your contract lab (b)(4). A corrective action approved by the firm’s quality unit was not documented.\n\nWe have reviewed your written response in which you state that “[the] Quality Department will be signing off on all finished product test results.” We are unable to evaluate the adequacy of your corrective action because you did not provide any test result records or other documentation to show the implementation of the new procedure.\n\n7. Your quality control operations for the MMR, the BPR, and manufacturing operations failed to include approving or rejecting any reprocessing, as required by 21 CFR 111.123(a)(5). For example, (b)(4) barrels of (b)(4) tablets (lot (b)(4)) were returned to the blending stage for grinding; however, the BPR does not include documentation showing that your quality control operations approved or rejected any reprocessing.\n\n8. Your quality control failed to document in the BPR at the time of performance the approval and release, or the rejection of a batch of dietary supplement for distribution, as required by 21 CFR 111.260(l)(3). For example, BPRs for (b)(4) (lot (b)(4) and (b)(4)) do not include documentation that your quality control personnel approved and released, or rejected, the batches for distribution.\n\nMisbranded Dietary Supplements\n\nIn addition, even if your (b)(4) product was not an unapproved new and misbranded drug, this product and others would be misbranded under section 403 of the Act because it does not comply with the labeling requirements for dietary supplements.\n\nSpecifically, we identified the following:\n\n1. Your (b)(4) and (b)(4) dietary supplement products are misbranded under section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling for your products does not comply with the labeling requirements for dietary supplements in 21 CFR 101.36. For example,\n\no Your (b)(4) Facts label fails to declare the source of the (b)(4). (21 CFR 101.36(d))\n\no Your (b)(4) Facts label incorrectly declares as a (b)(2)-dietary ingredient, “(b)(4)”. 21 CFR 101.9(c)(8)(iv) lists an RDI for (b)(4) of (b)(4) mcg based on the AI (adequate intake) that pertains only to (b)(4). (b)(4) should be listed as a (b)(3)-dietary ingredient.\n\no Your (b)(4) product fails to declare the source of the (b)(4) as indicated in the master manufacturing record; e.g., (b)(4) (as (b)(4)). (21 CFR 101.36(d))\n\no Your (b)(4) fails to express the metric quantitative amounts by weight per serving of other dietary ingredients in accordance with 21 CFR 101.36(b)(3)(ii)(A); for example, (b)(4) mg should be (b)(4)g.\n\no Your (b)(4) fails to declare the quantitative amount of (b)(4) with the % Daily Value based upon the presence of (b)(4) in the product formula, as required by 21 CFR 101.36(b)(2)\n\n2. Your (b)(4) product is misbranded within the meaning of section 403(w)(2) of the Act [21 U.S.C. § 343(w)(2)], in that the finished product labels fail to declare the major food allergen, shrimp and crab, as required by section 403(w)(1) of the Act. Specifically, as you have chosen to use a “Contains” statement, you must declare the specific type of Crustacean shellfish.\n\n3. Your (b)(4) product and (b)(4) products are each misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that each product label fails to declare the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically,\n\no Your (b)(4) Facts label declares the (b)(4) but fails to state the standardized common name “(b)(4)” as listed in the reference Herbs of Commerce, as incorporated by 21 CFR 101.4(h).\n\no Your (b)(4) product’s ingredient list declares “flavorless coating (Yellow 5, Red 40, Blue 1)” which is not the common or usual name of an ingredient. Furthermore, your batch production records for the product indicate “(b)(4)” as an ingredient but this ingredient does not appear in the ingredient list of your product label.\n\no Your (b)(4) Facts label declares the (b)(4) but fails to state the standardized common name “(b)(4)” as listed in Herbs of Commerce. [See 21 CFR 101.4(h)] Furthermore, the source ingredient (b)(4) fails to be listed first within the parentheses, and then followed by the (b)(4) name within parentheses; for example, (b)(4)\n\n4. Your (b)(4) product label is misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761 of the Act) may receive a report of a serious adverse event with such dietary supplement.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at the following email: dana.lewis@fda.hhs.gov (preferred), or you may mail a hard copy, addressed to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any further questions, please contact me at 214-253-5205 or by email.\n\nSincerely,\n\n\u002FS\u002F\n\nEdmundo Garcia\n\nProgram Division Director\n\nOffice of Human and Animal Food West, Division 3","Quality Supplement Manufacturing, Inc.","quality-supplement-manufacturing-inc-637182-12132022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquality-supplement-manufacturing-inc-637182-12132022","2026-10-26T08:09:46.151063+00:00","2023-02-07","637182","Dietary Supplements","Division of Pharmaceutical Quality Operations III","Raymundo Osuna","2026-08-20T01:16:25.139+00:00","Via Overnight Delivery","2022-12-13",{"id":56,"raw":57,"subject":12,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":19,"issuing_office":11,"recipient_name":71,"body_fetched_at":72,"delivery_method":29,"recipient_title":19,"reference_number":73,"action_taken_date":74,"medical_device_id":19,"response_letter_date":19},3693,[58,59,60,11,12,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-05T04:00:00Z\">06\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsante-manufacturing-inc-724931-06052026\">Sante Manufacturing Inc.  \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-94\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Wayne Kirby\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sante Manufacturing Inc.  \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>516 John Street N 11A &amp; 11B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Aylmer\u003C\u002Fspan> \u003Cspan>ON\u003C\u002Fspan> \u003Cspan>N5H 2B8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-94\u003C\u002Fp>\u003Cp>June 5, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Kirby:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our July 7, 2025, request and subsequent correspondence for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Sante Manufacturing Inc., FEI 3021535057, at 516 John Street N 11A &amp; 11B Aylmer, Ontario, Canada.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a component at high risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination, prior to its use in manufacturing. This includes testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in manufacturing drug products to determine its appropriate identity. Your firm also relied on the supplier’s certificate of analysis (COA) and accepted the \u003Cstrong>(b)(4)\u003C\u002Fstrong> component based on your supplier’s COA without establishing the reliability of your supplier’s test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See \u003Cstrong>(b)(4)\u003C\u002Fstrong> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Without adequate testing and confirmation of reliability of supplier test results, you lack scientific evidence that the components or drug products conform to appropriate specifications prior to use in the drug products you manufacture.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of parts \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the United States Pharmacopeia (USP) monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that you have adequately qualified your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Additionally, you did not demonstrate that you adequately monitor your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Because you use \u003Cstrong>(b)(4)\u003C\u002Fstrong> from this system as a component in your drug products, you should ensure that it meets, at a minimum, the USP \u003Cstrong>(b)(4) \u003C\u002Fstrong>monograph testing requirements and appropriate microbial limits in light of its intended use. Further, you did not demonstrate that you have an appropriate process validation program.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle along with associated procedures. Describe your program for process performance qualification (PPQ) and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and the information you provided, you did not demonstrate that your quality unit (QU) adequately exercises its authority and responsibilities including, but not limited to, implementing effective procedures and conducting adequate oversight of the drug products you manufacture. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of an appropriate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates \u003Cstrong>(21 CFR 211.166(a))\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Appropriate validation of your analytical methods \u003Cstrong>(21CFR 211.160(b))\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA guidance documents: \u003Cem>Q8(R2) Pharmaceutical Development \u003C\u002Fem>at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload,\u003Cem> Q9(R1) Quality Risk Management\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq9r1-quality-risk-management and \u003Cem>Q10 Pharmaceutical Quality System\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>A determination of whether procedures used by your firm are robust and appropriate\u003C\u002Fli>\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003C\u002Fli>\u003Cli>A complete and final review of each batch and its related information before the QU disposition decision\u003C\u002Fli>\u003Cli>Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on April 27, 2026.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Sante Manufacturing Inc., at 516 John Street N 11A &amp; 11B, Aylmer, Ontario, Canada, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3021535057 and ATTN: LaKeesha M. Sifontes.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nReference #:\n\n320-26-94\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Wayne Kirby\n\nRecipient Title\n\nOwner\n\nSante Manufacturing Inc.\n\n516 John Street N 11A & 11B\n\nAylmer ON N5H 2B8\n\nCanada\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-94\nJune 5, 2026\nDear Mr. Kirby:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our July 7, 2025, request and subsequent correspondence for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Sante Manufacturing Inc., FEI 3021535057, at 516 John Street N 11A & 11B Aylmer, Ontario, Canada.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures OTC drug products such as (b)(4). Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of incoming (b)(4), a component at high risk for (b)(4) contamination, prior to its use in manufacturing. This includes testing of (b)(4) used in manufacturing drug products to determine its appropriate identity. Your firm also relied on the supplier’s certificate of analysis (COA) and accepted the (b)(4) component based on your supplier’s COA without establishing the reliability of your supplier’s test analyses at appropriate intervals.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for (b)(4) contamination at (b)(4).\nWithout adequate testing and confirmation of reliability of supplier test results, you lack scientific evidence that the components or drug products conform to appropriate specifications prior to use in the drug products you manufacture.\nIn response to this letter, provide:\nA commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of parts (b)(4) of the United States Pharmacopeia (USP) monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nBased on the records and information you provided, you did not demonstrate that you have adequately qualified your (b)(4) system. Additionally, you did not demonstrate that you adequately monitor your (b)(4) system. Because you use (b)(4) from this system as a component in your drug products, you should ensure that it meets, at a minimum, the USP (b)(4) monograph testing requirements and appropriate microbial limits in light of its intended use. Further, you did not demonstrate that you have an appropriate process validation program.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle along with associated procedures. Describe your program for process performance qualification (PPQ) and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\nA timeline for performing appropriate PPQ for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) system. Ensure that the total count limits for your (b)(4) are appropriately stringent in view of the intended use of each of the products produced by your firm.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the system consistently produces (b)(4) that meets (b)(4) USP monograph specifications and appropriate microbial limits.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nBased on the records and the information you provided, you did not demonstrate that your quality unit (QU) adequately exercises its authority and responsibilities including, but not limited to, implementing effective procedures and conducting adequate oversight of the drug products you manufacture. For example, your QU failed to ensure:\nEstablishment of an appropriate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nAppropriate validation of your analytical methods (21CFR 211.160(b)).\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA guidance documents: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, Q9(R1) Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq9r1-quality-risk-management and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\nA determination of whether procedures used by your firm are robust and appropriate\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\nA complete and final review of each batch and its related information before the QU disposition decision\nOversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on April 27, 2026.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Sante Manufacturing Inc., at 516 John Street N 11A & 11B, Aylmer, Ontario, Canada, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3021535057 and ATTN: LaKeesha M. Sifontes.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Sante Manufacturing Inc.","sante-manufacturing-inc-724931-06052026","2026-08-19T04:06:48.349905+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsante-manufacturing-inc-724931-06052026","2026-10-26T08:09:53.900103+00:00","2026-06-16","724931","Drugs Over-the-Counter Drugs","Mr. Wayne Kirby","2026-08-19T04:36:49.687+00:00","320-26-94","2026-06-05",{"id":76,"raw":77,"subject":12,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":86,"fei_number":19,"letter_url":87,"updated_at":88,"action_type":22,"case_status":23,"posted_date":89,"marcs_cms_no":90,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":91,"body_fetched_at":92,"delivery_method":93,"recipient_title":19,"reference_number":94,"action_taken_date":95,"medical_device_id":19,"response_letter_date":19},928,[78,79,80,11,81,13,13,13],"\u003Ctime datetime=\"2025-04-29T04:00:00Z\">04\u002F29\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-09T04:00:00Z\">04\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdyno-manufacturing-inc-700785-04092025\">Dyno Manufacturing, Inc.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-63\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Jennifer A. Boofer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u002FQA Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Dyno Manufacturing, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2 Fox Industrial Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Madison\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>62060-1155\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-25-63\u003C\u002Fp>\u003Cp>April 9, 2025\u003Cbr>\u003Cbr>Dear Ms. Boofer:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Dyno Manufacturing, Inc., FEI 3017219182, at 2 Fox Industrial Dr., Madison, IL 62060-1155, from October 28 to November 1, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 21, 2024 response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter (OTC) hand sanitizer and antibacterial hand soap drug products without adequate assurance of the quality of raw materials. For example, you did not adequately test incoming raw materials, including identity testing of each shipment of each component lot (e.g., ethanol, glycerin, propylene glycol) used in the manufacture of your OTC drug products. You stated that you were aware of the legal requirement for testing components, but accepted the at-risk components based on their suppliers’ certificate of analysis (COA).\u003C\u002Fp>\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin you used in manufacturing your drug products to determine its appropriate identity.\u003C\u002Fp>\u003Cp>Identity testing for glycerin and certain other high-risk drug components include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Ethanol\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test your incoming ethanol, used as an active ingredient, for methanol. During the inspection, you indicated that your supplier tests ethanol for methanol prior to shipment. You relied on your suppliers’ COA, and you have not established the reliability of your component suppliers’ test analyses at appropriate intervals. In addition, the supplier’s COA for ethanol did not include test results for methanol.\u003C\u002Fp>\u003Cp>Without adequate testing you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPAs) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>Methanol testing for all hand sanitizer batches released and distributed in the United States within expiry.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to establish a stability testing program to support the expiry of your distributed drug products. You did not perform any stability studies for your OTC hand sanitizer and antibacterial hand soap drug products to support their assigned \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiry period. Also, you did not have an approved stability program procedure at the time of inspection.\u003C\u002Fp>\u003Cp>In your response, you commit to drafting stability protocols for all your hand sanitizer and antibacterial soap products and qualifying a contract laboratory to utilize their stability chambers for your stability studies. Your interim remediation is to test “representative retain samples” of your marketed products for assay to show stability under ambient conditions.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your interim remediation of testing your “retain samples” for assay does not address other critical quality attributes for drug stability, including microbiological and impurity testing.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your plan for continuing stability studies for your drug products through expiry, including detailed timelines. This plan should also include an assessment of the stability of drug product currently on the U.S. market.\u003C\u002Fli>\u003Cli>Your stability data to demonstrate that the chemical, purity, and microbiological properties of your drug products will remain within specification throughout their expiry period.\u003C\u002Fli>\u003Cli>Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid detailed definition of the specific attributes to be tested at each station (timepoint).\u003Cbr>o All procedures that describe these and other activities of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to validate your production and process controls. You did not have assurance that you are capable of consistently manufacturing your drug product with defined quality attributes. Your firm lacked a process validation program and data to support fundamental process parameters such as mixing speed, time, and temperature.\u003C\u002Fp>\u003Cp>From October 2022 to 2024, you manufactured approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of liquid OTC hand sanitizer and antibacterial hand soap drug products using unvalidated processes.\u003C\u002Fp>\u003Cp>Additionally, you did not perform equipment qualification studies, and the inspection documented that cleaning validation studies have not been completed for your drug product manufacturing equipment. You have not established evidence to show your equipment functions and operates as expected or that your cleaning processes for this equipment prevents product contamination.\u003C\u002Fp>\u003Cp>In your response, you commit to completing process validation studies and equipment qualification activities, however, your response is inadequate because you do not provide product impact assessments for ongoing manufacturing and distributed drug products.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See the FDA's guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing PPQ for each of your marketed drug products. Also include an explanation how you will ensure proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\u003C\u002Fli>\u003Cli>A risk assessment for the distributed drug product(s) produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not adequately exercise its authority and responsibilities including, but not limited to, implementing effective procedures and conducting adequate oversight. For example, you failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of written records describing the evaluation of quality standards of each drug product at least annually to determine the need for changes in drug product specifications, manufacturing, or control procedures (21 CFR 211.180(e)).\u003C\u002Fli>\u003Cli>Establishment of adequate written procedures defining QU responsibilities and controls (21 CFR 211.22(d)).\u003C\u002Fli>\u003Cli>Appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records as required by 21 CFR 211.68(b).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you initiated a CAPA to complete annual product reviews for all your liquid OTC hand sanitizers and antibacterial hand soaps manufactured. You also state under your effectiveness criteria, you will review and address data trends and implement CAPAs as appropriate based on your findings.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide information on how you will ensure annual product reviews will be completed routinely for all your drug products.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017219182 and ATTN: Sai Dharmaraj.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-63\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Jennifer A. Boofer\n\nRecipient Title\n\nGeneral Manager\u002FQA Manager\n\nDyno Manufacturing, Inc.\n\n2 Fox Industrial Dr.\n\nMadison, IL 62060-1155\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-63\nApril 9, 2025\n\nDear Ms. Boofer:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Dyno Manufacturing, Inc., FEI 3017219182, at 2 Fox Industrial Dr., Madison, IL 62060-1155, from October 28 to November 1, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 21, 2024 response to our Form FDA 483 in detail.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures over-the-counter (OTC) hand sanitizer and antibacterial hand soap drug products without adequate assurance of the quality of raw materials. For example, you did not adequately test incoming raw materials, including identity testing of each shipment of each component lot (e.g., ethanol, glycerin, propylene glycol) used in the manufacture of your OTC drug products. You stated that you were aware of the legal requirement for testing components, but accepted the at-risk components based on their suppliers’ certificate of analysis (COA).\nGlycerin\nYou failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin you used in manufacturing your drug products to determine its appropriate identity.\nIdentity testing for glycerin and certain other high-risk drug components include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nEthanol\nYou failed to adequately test your incoming ethanol, used as an active ingredient, for methanol. During the inspection, you indicated that your supplier tests ethanol for methanol prior to shipment. You relied on your suppliers’ COA, and you have not established the reliability of your component suppliers’ test analyses at appropriate intervals. In addition, the supplier’s COA for ethanol did not include test results for methanol.\nWithout adequate testing you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\nThe use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\nIn response to this letter, provide:\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPAs) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nMethanol testing for all hand sanitizer batches released and distributed in the United States within expiry.\n2. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\nYou failed to establish a stability testing program to support the expiry of your distributed drug products. You did not perform any stability studies for your OTC hand sanitizer and antibacterial hand soap drug products to support their assigned (b)(4) expiry period. Also, you did not have an approved stability program procedure at the time of inspection.\nIn your response, you commit to drafting stability protocols for all your hand sanitizer and antibacterial soap products and qualifying a contract laboratory to utilize their stability chambers for your stability studies. Your interim remediation is to test “representative retain samples” of your marketed products for assay to show stability under ambient conditions.\nYour response is inadequate. Your interim remediation of testing your “retain samples” for assay does not address other critical quality attributes for drug stability, including microbiological and impurity testing.\nIn response to this letter, provide:\nYour plan for continuing stability studies for your drug products through expiry, including detailed timelines. This plan should also include an assessment of the stability of drug product currently on the U.S. market.\nYour stability data to demonstrate that the chemical, purity, and microbiological properties of your drug products will remain within specification throughout their expiry period.\nYour action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid detailed definition of the specific attributes to be tested at each station (timepoint).\no All procedures that describe these and other activities of your remediated stability program.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYou failed to validate your production and process controls. You did not have assurance that you are capable of consistently manufacturing your drug product with defined quality attributes. Your firm lacked a process validation program and data to support fundamental process parameters such as mixing speed, time, and temperature.\nFrom October 2022 to 2024, you manufactured approximately (b)(4) batches of liquid OTC hand sanitizer and antibacterial hand soap drug products using unvalidated processes.\nAdditionally, you did not perform equipment qualification studies, and the inspection documented that cleaning validation studies have not been completed for your drug product manufacturing equipment. You have not established evidence to show your equipment functions and operates as expected or that your cleaning processes for this equipment prevents product contamination.\nIn your response, you commit to completing process validation studies and equipment qualification activities, however, your response is inadequate because you do not provide product impact assessments for ongoing manufacturing and distributed drug products.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee the FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing PPQ for each of your marketed drug products. Also include an explanation how you will ensure proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\nA risk assessment for the distributed drug product(s) produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not adequately exercise its authority and responsibilities including, but not limited to, implementing effective procedures and conducting adequate oversight. For example, you failed to ensure the following:\nEstablishment of written records describing the evaluation of quality standards of each drug product at least annually to determine the need for changes in drug product specifications, manufacturing, or control procedures (21 CFR 211.180(e)).\nEstablishment of adequate written procedures defining QU responsibilities and controls (21 CFR 211.22(d)).\nAppropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records as required by 21 CFR 211.68(b).\nIn your response, you initiated a CAPA to complete annual product reviews for all your liquid OTC hand sanitizers and antibacterial hand soaps manufactured. You also state under your effectiveness criteria, you will review and address data trends and implement CAPAs as appropriate based on your findings.\nYour response is inadequate. You do not provide information on how you will ensure annual product reviews will be completed routinely for all your drug products.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017219182 and ATTN: Sai Dharmaraj.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Dyno Manufacturing, Inc.","dyno-manufacturing-inc-700785-04092025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdyno-manufacturing-inc-700785-04092025","2026-10-26T08:08:28.949733+00:00","2025-04-29","700785","Ms. Jennifer A. Boofer","2026-08-19T16:50:06.657+00:00","Via Email","320-25-63","2025-04-09",{"id":97,"raw":98,"subject":102,"body_html":103,"body_text":104,"firm_name":105,"letter_id":106,"created_at":18,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":23,"posted_date":109,"marcs_cms_no":110,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":111,"body_fetched_at":112,"delivery_method":113,"recipient_title":19,"reference_number":19,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},450,[99,100,101,11,102,13,13,13],"\u003Ctime datetime=\"2025-12-02T05:00:00Z\">12\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fturbare-manufacturing-713516-09162025\">Turbare Manufacturing\u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Laura Martin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Turbare Manufacturing\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>925 Jeanette Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Conway\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>72032-6651\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>WL # 713516\u003C\u002Fp>\u003Cp>September 16, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Martin:\u003C\u002Fp>\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on June 23, 2023, and most recently on January 25, 2025. From January 14, 2025, to January 24, 2025, an FDA investigator inspected your facility, Turbare Manufacturing, located at 925 Jeanette Drive, Conway, Arkansas 72032. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to your facility on January 24, 2025. We reviewed your February 14, 2025, and April 30, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. FDA also acknowledges that, on February 18, 2025, your firm initiated a voluntary recall of Bevacizumab 1.25mg\u002F0.05mL in 0.25mL Syringe, Lot # 12192024\u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # 12122024\u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to lack of sterility assurance. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003C\u002Fp>\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\u003C\u002Fp>\u003Cp>1. Your firm failed to conduct process simulation (media fill) studies that closely simulate aseptic production operations under the worst-case, most challenging, and stressful conditions.\u003C\u002Fp>\u003Cp>The FDA investigator also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\u003Cp>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\u003Cp>2. Your firm failed to establish acceptance criteria for the sampling and testing conducted by the quality control unit that are adequate to assure that batches of drug products meet appropriate statistical quality control criteria as a condition for their approval and release (21 CFR 211.165(d)).\u003C\u002Fp>\u003Cp>3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic processes (21 CFR 211.113(b)).\u003C\u002Fp>\u003Cp>4. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your facility’s responses to the Form FDA 483. We also acknowledge your voluntary recall of Bevacizumab 1.25mg\u002F0.05mL in 0.25mL Syringe, Lot # 12192024\u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # 12122024\u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to lack of sterility assurance.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear deficient:\u003C\u002Fp>\u003Cp>1. Regarding your firm’s failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed:\u003C\u002Fp>\u003Cp>a. We acknowledge the actions taken by your firm in response to your failure to investigate the recovery of 1 cfu mold (i.e., \u003Cem>Curvularia intermedia\u003C\u002Fem>) from an operator’s \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample during personnel monitoring, performed in association with (aseptic processing) media fill lot # 11252024\u003Cstrong>(b)(4)\u003C\u002Fstrong>, including Investigation Record # NCR-25-002 and Document Change Request # DCR-071, as well as updates to\u002Fimplementation of the following documents: SOP-048 (\u003Cem>Routine Environmental Monitoring\u003C\u002Fem>), TEM-034 (\u003Cem>EM Investigation Template\u003C\u002Fem>), and SOP-088 (\u003Cem>Reading of Microbiological Culture Media\u003C\u002Fem>). However, while your investigation attempts to identify the source and impact of the contamination, you failed to determine why the excursion itself was not investigated at the time of occurrence. Consequently, there is no assurance of your ability to initiate investigations in a timely manner. Furthermore, your investigation concludes the likely root cause of the excursion was “\u003Cem>ineffective cleaning, due to stressing the environment for Media Fill\u003C\u002Fem>…” While process simulation (i.e., media-fill) studies should be conducted under “worst-case” scenarios (e.g., simulating largest batch size, longest processing time, and routine &amp; non-routine interventions), they should also be conducted in accordance with all related approved procedures (e.g., cleaning procedures).\u003C\u002Fp>\u003Cp>Consequently, the intentional lack of cleaning may confound the results of the media fill study. Your response suggests your process simulation procedures should be reassessed and modified, as necessary.\u003C\u002Fp>\u003Cp>b. We acknowledge actions taken by your firm in response to your failure to investigate the recovery of 1 cfu from an operator’s \u003Cstrong>(b)(4)\u003C\u002Fstrong> fingertip sample, performed in association with the production of Bevacizumab 1.25mg\u002F0.05mL in 0.25mL syringes, Lot # 11132024\u003Cstrong>(b)(4)\u003C\u002Fstrong> in BSC 0003, including the closure of DCR-071, updates to SOP-048, and the implementation of TEM-034, etc. However, we note that while section 6.10.1 of SOP-048 (\u003Cem>Routine Environmental Monitoring\u003C\u002Fem>) reads in part “…investigations are targeted for closure within \u003Cstrong>(b)(4)\u003C\u002Fstrong> from initiation,” it does not appear to specify a time frame within which such investigations must be initiated. Consequently, there’s no procedural safeguard to prevent delays in initiating investigations into environmental monitoring excursions.\u003C\u002Fp>\u003Cp>c. We acknowledge actions taken by your firm in response to your failure to identify and investigate the failure of two batches of drug product (i.e., Bevacizumab, Lot # 12122024\u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # 12192024\u003Cstrong>(b)(4)\u003C\u002Fstrong>) to comply with appropriate Acceptable Quality Limits (AQL) for visible particulates. We acknowledged the voluntary recall of the two aforementioned lots of drug product, as well as revisions to SOP-075 (\u003Cem>Acceptable Quality Limit (AQL)\u003C\u002Fem>), which align with the generally acceptable standards established in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, we remain concerned with conclusions derived from Incident ID # INC-25-002, specifically your contention the batches in question were acceptable based on an examination of an additional \u003Cstrong>(b)(4)\u003C\u002Fstrong> units from retain samples of each of the lots. For example, per document number FRM-071 (Version 02, 12 DEC2024), your “AQL” at the time the batches were produced was \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Your defect rates for those categorized as “Major” were erroneously calculated as 0.3% and 0.1% for Lot # 12192024\u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # 12122024\u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively. However, the rate should be calculated based on the actual sample size (i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong> units), which results in a 13.3% and 6.7% “Major” defect rate for Lot # 12192024\u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # 12122024\u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively, which should have triggered a non-conformance investigation. Your retrospective investigation fails to address this deficiency.\u003C\u002Fp>\u003Cp>2. Regarding your firm’s failure to establish acceptance criteria for the sampling and testing conducted by the quality control unit that are adequate to assure that batches of drug products meet appropriate statistical quality control criteria as a condition for their approval and release:\u003C\u002Fp>\u003Cp>a. We acknowledge actions taken by your firm in response to your failure to establish statistically valid sampling plans as part of your visual inspection program. Specifically, we acknowledge updates to SOP-075 (\u003Cem>Acceptable Quality Limit (AQL)\u003C\u002Fem>), including the implementation of AQL sampling plans consistent with generally accepted standards for acceptance sampling by attribute (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) for your visual inspection processes. We also note you established process flow charts to guide the decision matrix when either the 100% visual inspection or an AQL inspection fail. According to your process (i.e., per SOP-075), the failure of the initial 100% visual inspection for critical defects triggers a non-conformance investigation. However, you failed to provide a rationale for allowing a second 100% visual inspection, without an investigation in cases where the initial 100% visual inspection fails for minor and\u002For major defects.\u003C\u002Fp>\u003Cp>3. Regarding your firm’s failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic processes:\u003C\u002Fp>\u003Cp>a. We acknowledge your firm’s actions, taken in response to your failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most challenging, and stressful conditions, pursuant to an approved written study protocol. We recognize the distinction between aseptic personnel qualification procedures and aseptic process simulation (i.e., media fills). Our review of the document titled \u003Cem>Summary Report for Syringe Repackaging Media Fill – 0.25 ml\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicates a single batch (Lot # 01312025\u003Cstrong>(b)(4)\u003C\u002Fstrong>) was produced on 01\u002F31\u002F2025 yielding a total of \u003Cstrong>(b)(4)\u003C\u002Fstrong> units (i.e., syringes). The summary report and associated batch records indicate that 25 “Major” defects were identified during the initial 100% visual inspection process, all for “fill volume” defects. This equates to a \u003Cstrong>(b)(4)\u003C\u002Fstrong>% Major defect rate, under the \u003Cstrong>(b)(4)\u003C\u002Fstrong>% Defect Alert Limit established by SOP-061 \u003Cem>100% Visual Inspection of Injectable Product\u003C\u002Fem>. The report further indicates “…\u003Cem> no variances observed during the execution of the MFP-025-001\u003C\u002Fem>.” Review of the batch records associated with the media fill indicate that routine and non-routine interventions (e.g., goggle adjustment, spill clean-up, simulated break\u002Fshift-change; as well as excessive filling time, batch size, and vial punctures), were employed. However, it is also observed that in accordance with SOP-074, you omitted routine cleaning of the ISO\u003Cstrong>(b)(4)\u003C\u002Fstrong> room and ISO\u003Cstrong>(b)(4)\u003C\u002Fstrong> hood prior to production. While it is important to simulate the aseptic process under worst-case, most stressful conditions, it is not appropriate to omit routine pre-production cleaning as this may skew the results. For example, if a microbial excursion is encountered, either in environmental monitoring results or sterility testing results, the root cause may be falsely attributed to the lack of routine, pre-production cleaning, instead of a potential breach in, for example, aseptic technique (e.g., failure to disinfect gloved hands), etc. Furthermore, it is noted this was considered a “requalification” activity. As such, only one full-scale batch was produced. However, since the media fill batches, produced in May 2024, were not considered adequate due to the failure to include routine\u002Fnon-routine interventions, this protocol should have been treated as an initial media-fill qualification activity consisting of three successful, consecutive full-scale batches.\u003C\u002Fp>\u003Cp>4. Regarding your firm’s failure to establish an adequate system for monitoring environmental conditions in aseptic processing areas:\u003C\u002Fp>\u003Cp>a. We acknowledge your firm’s actions, taken in response to your failure to implement written procedures which adequately describe the process for investigating environmental monitoring excursions. We recognize enhancements made to SOP-048 (\u003Cem>Environmental Monitoring Program\u003C\u002Fem>), including section 6.10.1 which describes the processes for conducting EM Investigations. It is noted the procedure requires an evaluation of related documents, including cleaning records, equipment records, batch production records, operator qualification, etc. The procedure also requires that a root cause analysis and impact assessment be performed, concluding with a recommendation regarding batch disposition, where applicable. We further note the procedure reads, in part “…\u003Cem>actionable environmental or personnel monitoring recoveries require a documented investigation into the potential root cause and subsequent impact… investigations are targeted for closure within\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>from initiation\u003C\u002Fem>.” However, as noted in item 1(b), above, it does not appear to specify a time frame within which such investigations must be initiated. Consequently, there is no procedural safeguard to prevent delays in initiating investigations into environmental and personnel monitoring excursions.\u003C\u002Fp>\u003Cp>Furthermore, according to section 6.4 of SOP-048, active viable air monitoring of the ISO\u003Cstrong>(b)(4)\u003C\u002Fstrong> area is conducted “\u003Cem>At least \u003C\u002Fem>\u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>per Production Batch\u003C\u002Fem>.” However, review of the media fill batch production records for Lot # 01312025\u003Cstrong>(b)(4)\u003C\u002Fstrong> indicates it can take over \u003Cstrong>(b)(4)\u003C\u002Fstrong> to complete the syringe repackaging process alone. Consequently, your active air sampling process does not adequately reflect environmental conditions throughout the aseptic production process.\u003C\u002Fp>\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>All correspondence should refer to the Warning Letter Number above (# 713516) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>F. Gail Bormel, JD, RPh\u003Cbr>Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLaura Martin\n\nRecipient Title\n\nCEO\n\nTurbare Manufacturing\n\n925 Jeanette Drive\n\nConway, AR 72032-6651\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nWL # 713516\nSeptember 16, 2025\nDear Ms. Martin:\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on June 23, 2023, and most recently on January 25, 2025. From January 14, 2025, to January 24, 2025, an FDA investigator inspected your facility, Turbare Manufacturing, located at 925 Jeanette Drive, Conway, Arkansas 72032. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\nFDA issued a Form FDA 483 to your facility on January 24, 2025. We reviewed your February 14, 2025, and April 30, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. FDA also acknowledges that, on February 18, 2025, your firm initiated a voluntary recall of Bevacizumab 1.25mg\u002F0.05mL in 0.25mL Syringe, Lot # 12192024(b)(4) and Lot # 12122024(b)(4), due to lack of sterility assurance. Based on this inspection, it appears you produced drugs that violate the FDCA.\nA. Compounded Drug Products under the FDCA\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\nB. Violations of the FDCA\nAdulterated Drug Products\nThe FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\n1. Your firm failed to conduct process simulation (media fill) studies that closely simulate aseptic production operations under the worst-case, most challenging, and stressful conditions.\nThe FDA investigator also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n2. Your firm failed to establish acceptance criteria for the sampling and testing conducted by the quality control unit that are adequate to assure that batches of drug products meet appropriate statistical quality control criteria as a condition for their approval and release (21 CFR 211.165(d)).\n3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic processes (21 CFR 211.113(b)).\n4. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nC. Corrective Actions\nWe have reviewed your facility’s responses to the Form FDA 483. We also acknowledge your voluntary recall of Bevacizumab 1.25mg\u002F0.05mL in 0.25mL Syringe, Lot # 12192024(b)(4) and Lot # 12122024(b)(4), due to lack of sterility assurance.\nSome of your corrective actions appear deficient:\n1. Regarding your firm’s failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed:\na. We acknowledge the actions taken by your firm in response to your failure to investigate the recovery of 1 cfu mold (i.e., Curvularia intermedia) from an operator’s (b)(4) sample during personnel monitoring, performed in association with (aseptic processing) media fill lot # 11252024(b)(4), including Investigation Record # NCR-25-002 and Document Change Request # DCR-071, as well as updates to\u002Fimplementation of the following documents: SOP-048 (Routine Environmental Monitoring), TEM-034 (EM Investigation Template), and SOP-088 (Reading of Microbiological Culture Media). However, while your investigation attempts to identify the source and impact of the contamination, you failed to determine why the excursion itself was not investigated at the time of occurrence. Consequently, there is no assurance of your ability to initiate investigations in a timely manner. Furthermore, your investigation concludes the likely root cause of the excursion was “ineffective cleaning, due to stressing the environment for Media Fill…” While process simulation (i.e., media-fill) studies should be conducted under “worst-case” scenarios (e.g., simulating largest batch size, longest processing time, and routine & non-routine interventions), they should also be conducted in accordance with all related approved procedures (e.g., cleaning procedures).\nConsequently, the intentional lack of cleaning may confound the results of the media fill study. Your response suggests your process simulation procedures should be reassessed and modified, as necessary.\nb. We acknowledge actions taken by your firm in response to your failure to investigate the recovery of 1 cfu from an operator’s (b)(4) fingertip sample, performed in association with the production of Bevacizumab 1.25mg\u002F0.05mL in 0.25mL syringes, Lot # 11132024(b)(4) in BSC 0003, including the closure of DCR-071, updates to SOP-048, and the implementation of TEM-034, etc. However, we note that while section 6.10.1 of SOP-048 (Routine Environmental Monitoring) reads in part “…investigations are targeted for closure within (b)(4) from initiation,” it does not appear to specify a time frame within which such investigations must be initiated. Consequently, there’s no procedural safeguard to prevent delays in initiating investigations into environmental monitoring excursions.\nc. We acknowledge actions taken by your firm in response to your failure to identify and investigate the failure of two batches of drug product (i.e., Bevacizumab, Lot # 12122024(b)(4) and Lot # 12192024(b)(4)) to comply with appropriate Acceptable Quality Limits (AQL) for visible particulates. We acknowledged the voluntary recall of the two aforementioned lots of drug product, as well as revisions to SOP-075 (Acceptable Quality Limit (AQL)), which align with the generally acceptable standards established in (b)(4). However, we remain concerned with conclusions derived from Incident ID # INC-25-002, specifically your contention the batches in question were acceptable based on an examination of an additional (b)(4) units from retain samples of each of the lots. For example, per document number FRM-071 (Version 02, 12 DEC2024), your “AQL” at the time the batches were produced was (b)(4)%. Your defect rates for those categorized as “Major” were erroneously calculated as 0.3% and 0.1% for Lot # 12192024(b)(4) and Lot # 12122024(b)(4), respectively. However, the rate should be calculated based on the actual sample size (i.e., (b)(4) units), which results in a 13.3% and 6.7% “Major” defect rate for Lot # 12192024(b)(4) and Lot # 12122024(b)(4), respectively, which should have triggered a non-conformance investigation. Your retrospective investigation fails to address this deficiency.\n2. Regarding your firm’s failure to establish acceptance criteria for the sampling and testing conducted by the quality control unit that are adequate to assure that batches of drug products meet appropriate statistical quality control criteria as a condition for their approval and release:\na. We acknowledge actions taken by your firm in response to your failure to establish statistically valid sampling plans as part of your visual inspection program. Specifically, we acknowledge updates to SOP-075 (Acceptable Quality Limit (AQL)), including the implementation of AQL sampling plans consistent with generally accepted standards for acceptance sampling by attribute (e.g., (b)(4)) for your visual inspection processes. We also note you established process flow charts to guide the decision matrix when either the 100% visual inspection or an AQL inspection fail. According to your process (i.e., per SOP-075), the failure of the initial 100% visual inspection for critical defects triggers a non-conformance investigation. However, you failed to provide a rationale for allowing a second 100% visual inspection, without an investigation in cases where the initial 100% visual inspection fails for minor and\u002For major defects.\n3. Regarding your firm’s failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic processes:\na. We acknowledge your firm’s actions, taken in response to your failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most challenging, and stressful conditions, pursuant to an approved written study protocol. We recognize the distinction between aseptic personnel qualification procedures and aseptic process simulation (i.e., media fills). Our review of the document titled Summary Report for Syringe Repackaging Media Fill – 0.25 ml (b)(4) indicates a single batch (Lot # 01312025(b)(4)) was produced on 01\u002F31\u002F2025 yielding a total of (b)(4) units (i.e., syringes). The summary report and associated batch records indicate that 25 “Major” defects were identified during the initial 100% visual inspection process, all for “fill volume” defects. This equates to a (b)(4)% Major defect rate, under the (b)(4)% Defect Alert Limit established by SOP-061 100% Visual Inspection of Injectable Product. The report further indicates “… no variances observed during the execution of the MFP-025-001.” Review of the batch records associated with the media fill indicate that routine and non-routine interventions (e.g., goggle adjustment, spill clean-up, simulated break\u002Fshift-change; as well as excessive filling time, batch size, and vial punctures), were employed. However, it is also observed that in accordance with SOP-074, you omitted routine cleaning of the ISO(b)(4) room and ISO(b)(4) hood prior to production. While it is important to simulate the aseptic process under worst-case, most stressful conditions, it is not appropriate to omit routine pre-production cleaning as this may skew the results. For example, if a microbial excursion is encountered, either in environmental monitoring results or sterility testing results, the root cause may be falsely attributed to the lack of routine, pre-production cleaning, instead of a potential breach in, for example, aseptic technique (e.g., failure to disinfect gloved hands), etc. Furthermore, it is noted this was considered a “requalification” activity. As such, only one full-scale batch was produced. However, since the media fill batches, produced in May 2024, were not considered adequate due to the failure to include routine\u002Fnon-routine interventions, this protocol should have been treated as an initial media-fill qualification activity consisting of three successful, consecutive full-scale batches.\n4. Regarding your firm’s failure to establish an adequate system for monitoring environmental conditions in aseptic processing areas:\na. We acknowledge your firm’s actions, taken in response to your failure to implement written procedures which adequately describe the process for investigating environmental monitoring excursions. We recognize enhancements made to SOP-048 (Environmental Monitoring Program), including section 6.10.1 which describes the processes for conducting EM Investigations. It is noted the procedure requires an evaluation of related documents, including cleaning records, equipment records, batch production records, operator qualification, etc. The procedure also requires that a root cause analysis and impact assessment be performed, concluding with a recommendation regarding batch disposition, where applicable. We further note the procedure reads, in part “…actionable environmental or personnel monitoring recoveries require a documented investigation into the potential root cause and subsequent impact… investigations are targeted for closure within (b)(4) from initiation.” However, as noted in item 1(b), above, it does not appear to specify a time frame within which such investigations must be initiated. Consequently, there is no procedural safeguard to prevent delays in initiating investigations into environmental and personnel monitoring excursions.\nFurthermore, according to section 6.4 of SOP-048, active viable air monitoring of the ISO(b)(4) area is conducted “At least (b)(4) per Production Batch.” However, review of the media fill batch production records for Lot # 01312025(b)(4) indicates it can take over (b)(4) to complete the syringe repackaging process alone. Consequently, your active air sampling process does not adequately reflect environmental conditions throughout the aseptic production process.\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\nD. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nAll correspondence should refer to the Warning Letter Number above (# 713516) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nF. Gail Bormel, JD, RPh\nDirector\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________________\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).","Turbare Manufacturing","turbare-manufacturing-713516-09162025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fturbare-manufacturing-713516-09162025","2026-10-26T08:10:15.821423+00:00","2025-12-02","713516","Laura Martin","2026-08-19T12:25:43.202+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2025-09-16",{"id":116,"raw":117,"subject":122,"body_html":123,"body_text":124,"firm_name":125,"letter_id":126,"created_at":18,"fei_number":19,"letter_url":127,"updated_at":128,"action_type":22,"case_status":23,"posted_date":129,"marcs_cms_no":130,"product_type":131,"closeout_date":19,"issuing_office":121,"recipient_name":19,"body_fetched_at":132,"delivery_method":133,"recipient_title":19,"reference_number":134,"action_taken_date":135,"medical_device_id":19,"response_letter_date":19},208,[118,119,120,121,122,13,13,13],"\u003Ctime datetime=\"2026-04-23T04:00:00Z\">04\u002F23\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-21T04:00:00Z\">04\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdaily-manufacturing-solutions-inc-728255-04212026\">Daily Manufacturing Solutions Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2601477\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Daily Manufacturing Solutions Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9119 Milliken Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Rancho Cucamonga\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91730\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 21, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Daily Manufacturing Solutions Inc. manufactures, sells and\u002For distributes nicotine pouch products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you manufacture and offer for sale or distribution to customers in the United States nicotine pouch products that lack a marketing authorization order, including: PUCK COOL MINT 6MG.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketingorders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2601477, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>FDA Center for Tobacco Products\u003Cbr>c\u002Fo Document Control Center\u003Cbr>Building 71, Room G335\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Ele Ibarra-Pratt\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>cc:\u003Cbr>Puck LLC\u003Cbr>818 13th Street\u003Cbr>Tuscaloosa, AL 35401\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2601477\n\nProduct:\n\nTobacco\n\nRecipient:\n\nDaily Manufacturing Solutions Inc.\n\n9119 Milliken Avenue\n\nRancho Cucamonga, CA 91730\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nApril 21, 2026\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Daily Manufacturing Solutions Inc. manufactures, sells and\u002For distributes nicotine pouch products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you manufacture and offer for sale or distribution to customers in the United States nicotine pouch products that lack a marketing authorization order, including: PUCK COOL MINT 6MG.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketingorders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2601477, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nEle Ibarra-Pratt\nActing Director\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\ncc:\nPuck LLC\n818 13th Street\nTuscaloosa, AL 35401","Daily Manufacturing Solutions Inc.","daily-manufacturing-solutions-inc-728255-04212026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdaily-manufacturing-solutions-inc-728255-04212026","2026-10-26T08:08:20.987148+00:00","2026-04-23","728255","Tobacco","2026-08-19T04:46:02.728+00:00","VIA UPS and Electronic Mail","ER2601477","2026-04-21",{"id":137,"raw":138,"subject":12,"body_html":142,"body_text":143,"firm_name":144,"letter_id":145,"created_at":18,"fei_number":19,"letter_url":146,"updated_at":147,"action_type":22,"case_status":23,"posted_date":148,"marcs_cms_no":149,"product_type":70,"closeout_date":19,"issuing_office":11,"recipient_name":150,"body_fetched_at":151,"delivery_method":93,"recipient_title":19,"reference_number":152,"action_taken_date":153,"medical_device_id":19,"response_letter_date":19},361,[139,140,141,11,12,13,13,13],"\u003Ctime datetime=\"2026-01-27T05:00:00Z\">01\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-14T05:00:00Z\">01\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffulijaya-manufacturing-sdn-bhd-719172-01142026\">Fulijaya Manufacturing SDN. BHD.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-37\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Soo Nam Tan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Group Executive Chairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Fulijaya Manufacturing SDN. BHD.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 30, Loring Makmur 13\u002F1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Taman Makmur Industrial Estate\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>09000\u003C\u002Fspan> \u003Cspan>Kulim\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kedah\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Malaysia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:soonamtan@yahoo.com\"> soonamtan@yahoo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-26-37\u003C\u002Fp>\u003Cp>January 14, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Tan:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fulijaya Manufacturing SDN. BHD., FEI 1000291174, at No. 30, Loring Makmur 13\u002F1, Taman Makmur Industrial Estate, Kulim, Kedah, from July 14 to 18, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your August 6, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your laboratory records lacked complete and original data to support the analyses performed. For example, our investigator asked for raw data for microbiological release and stability testing of your over-the-counter (OTC) drug products prior to May 2025 and your firm’s representative stated that the logbooks were not available.\u003C\u002Fp>\u003Cp>Reliability of data is fundamentally compromised when there is a failure to record or maintain complete and accurate records of test results or conditions associated with all tests. Furthermore, the lack of reliable data compromises the quality unit’s ability to exercise its function of ensuring compliance to applicable standards.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to demonstrate that your microbiological test methods were appropriate to assure your drug products and components conform to appropriate standards of quality and purity. Specifically, you failed to conduct growth promotion testing of your microbiological media to assure suitability before use in release and stability testing of your drug products. Additionally, you lacked appropriate sampling and testing to ensure \u003Cstrong>(b)(4)\u003C\u002Fstrong> used as a component in your drug products is suitable for its intended use as you did not perform testing for \u003Cem>Burkholderia cepacia complex\u003C\u002Fem> (BCC).\u003C\u002Fp>\u003Cp>In your response, you acknowledged that your firm accepted media growth promotion testing solely based on the supplier’s certificate of analysis (CoA) without independent verification. You also acknowledged that your firm did not perform suitability testing and did not evaluate your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system for BCC. Your firm committed to using a qualified third-party laboratory to verify the quality of growth media and to perform suitability testing, as well as initiate sampling and testing of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system for BCC. Your response is inadequate. Notably, your response stated that a review of internal microbial limit testing data from recent years indicates that microbial detection has been achievable, demonstrating the effectiveness of the current testing process. However, as noted in this letter, your internal microbial limit testing is flawed.\u003C\u002Fp>\u003Cp>The ability of microbial testing methods to detect objectionable microorganisms in the presence of each drug product must be established. Results generated using unverified or unvalidated methods may put consumers at risk.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods and date validated and\u002For verified, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A retrospective risk assessment of prior testing to assure suitability of all growth media for the last three years of drug microbiological testing to ensure reliable microbial enumeration and appropriate identification of objectionable microorganisms.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not have adequate stability data to demonstrate that the quality attributes of your drug products remain acceptable throughout the labeled expiry period. Assay testing for each active ingredient in your drug products was not being performed at each of your pre-determined timepoint intervals. Furthermore, your firm did not establish appropriate limits for impurities or evaluate your drug products for the presence of impurities.\u003C\u002Fp>\u003Cp>Your firm’s response is inadequate. You provided accelerated stability data for your drug products, but you did not include testing for all active ingredients and impurities. For example, the stability data for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> lacked testing for one of the active ingredients, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and impurities.\u003C\u002Fp>\u003Cp>Furthermore, in a November 12, 2024 communication your firm committed to updating your stability testing procedures to require active ingredient testing. This communication was a response to a request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4).\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Use of a Contract Laboratory\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as testing laboratories. FDA regards contractors as extensions of the manufacturer. For example, contract testing laboratories performing specific identity testing of drug components (e.g., the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP) must use verified USP methods.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide, particularly with \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. Your firm should perform an assessment of all testing performed by contract laboratories to ensure that the methods being utilized have been appropriately validated and\u002For verified. See FDA’s guidance document \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003Cbr>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003Cbr>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003Cbr>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Fulijaya Manufacturing SDN. BHD., No. 30, Loring Makmur 13\u002F1, Taman Makmur Industrial Estate, Kulim, Kedah, Malaysia into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000291174 and ATTN: Ernest Bizjak.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-26-37\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Soo Nam Tan\n\nRecipient Title\n\nGroup Executive Chairman\n\nFulijaya Manufacturing SDN. BHD.\n\nNo. 30, Loring Makmur 13\u002F1\n\nTaman Makmur Industrial Estate\n\n09000 Kulim\n\nKedah\n\nMalaysia\n\nsoonamtan@yahoo.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-37\nJanuary 14, 2026\nDear Mr. Tan:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fulijaya Manufacturing SDN. BHD., FEI 1000291174, at No. 30, Loring Makmur 13\u002F1, Taman Makmur Industrial Estate, Kulim, Kedah, from July 14 to 18, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your August 6, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\nYour laboratory records lacked complete and original data to support the analyses performed. For example, our investigator asked for raw data for microbiological release and stability testing of your over-the-counter (OTC) drug products prior to May 2025 and your firm’s representative stated that the logbooks were not available.\nReliability of data is fundamentally compromised when there is a failure to record or maintain complete and accurate records of test results or conditions associated with all tests. Furthermore, the lack of reliable data compromises the quality unit’s ability to exercise its function of ensuring compliance to applicable standards.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nYour firm failed to demonstrate that your microbiological test methods were appropriate to assure your drug products and components conform to appropriate standards of quality and purity. Specifically, you failed to conduct growth promotion testing of your microbiological media to assure suitability before use in release and stability testing of your drug products. Additionally, you lacked appropriate sampling and testing to ensure (b)(4) used as a component in your drug products is suitable for its intended use as you did not perform testing for Burkholderia cepacia complex (BCC).\nIn your response, you acknowledged that your firm accepted media growth promotion testing solely based on the supplier’s certificate of analysis (CoA) without independent verification. You also acknowledged that your firm did not perform suitability testing and did not evaluate your (b)(4) system for BCC. Your firm committed to using a qualified third-party laboratory to verify the quality of growth media and to perform suitability testing, as well as initiate sampling and testing of your (b)(4) system for BCC. Your response is inadequate. Notably, your response stated that a review of internal microbial limit testing data from recent years indicates that microbial detection has been achievable, demonstrating the effectiveness of the current testing process. However, as noted in this letter, your internal microbial limit testing is flawed.\nThe ability of microbial testing methods to detect objectionable microorganisms in the presence of each drug product must be established. Results generated using unverified or unvalidated methods may put consumers at risk.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of chemical and microbial specifications, including test methods and date validated and\u002For verified, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA retrospective risk assessment of prior testing to assure suitability of all growth media for the last three years of drug microbiological testing to ensure reliable microbial enumeration and appropriate identification of objectionable microorganisms.\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nYour firm did not have adequate stability data to demonstrate that the quality attributes of your drug products remain acceptable throughout the labeled expiry period. Assay testing for each active ingredient in your drug products was not being performed at each of your pre-determined timepoint intervals. Furthermore, your firm did not establish appropriate limits for impurities or evaluate your drug products for the presence of impurities.\nYour firm’s response is inadequate. You provided accelerated stability data for your drug products, but you did not include testing for all active ingredients and impurities. For example, the stability data for your (b)(4) lacked testing for one of the active ingredients, (b)(4), and impurities.\nFurthermore, in a November 12, 2024 communication your firm committed to updating your stability testing procedures to require active ingredient testing. This communication was a response to a request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4).\nIn response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\nAll procedures that describe these and other elements of your remediated stability program.\nUse of a Contract Laboratory\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as testing laboratories. FDA regards contractors as extensions of the manufacturer. For example, contract testing laboratories performing specific identity testing of drug components (e.g., the presence of (b)(4) in (b)(4) USP) must use verified USP methods.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide, particularly with (b)(4) drug products. Your firm should perform an assessment of all testing performed by contract laboratories to ensure that the methods being utilized have been appropriately validated and\u002For verified. See FDA’s guidance document (b)(4).\nYou are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nQuality Systems\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Fulijaya Manufacturing SDN. BHD., No. 30, Loring Makmur 13\u002F1, Taman Makmur Industrial Estate, Kulim, Kedah, Malaysia into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000291174 and ATTN: Ernest Bizjak.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Fulijaya Manufacturing SDN. BHD.","fulijaya-manufacturing-sdn-bhd-719172-01142026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffulijaya-manufacturing-sdn-bhd-719172-01142026","2026-10-26T08:08:43.953658+00:00","2026-01-27","719172","Mr. Soo Nam Tan","2026-08-19T07:16:35.649+00:00","320-26-37","2026-01-14",{"id":155,"raw":156,"subject":122,"body_html":160,"body_text":161,"firm_name":162,"letter_id":163,"created_at":164,"fei_number":19,"letter_url":165,"updated_at":166,"action_type":22,"case_status":23,"posted_date":167,"marcs_cms_no":168,"product_type":131,"closeout_date":19,"issuing_office":121,"recipient_name":169,"body_fetched_at":170,"delivery_method":133,"recipient_title":19,"reference_number":19,"action_taken_date":171,"medical_device_id":19,"response_letter_date":19},2777,[157,158,159,121,122,13,13,13],"\u003Ctime datetime=\"2022-04-05T13:20:00Z\">04\u002F05\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-10T05:00:00Z\">12\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ften-days-manufacturing-dba-daily-manufacturing-623001-12102021\">Ten Days Manufacturing d\u002Fb\u002Fa Daily Manufacturing\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Syed Raza Razavi, Mohammed Shabeer Humkar, and Akbar Ali Razavi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Ten Days Manufacturing d\u002Fb\u002Fa Daily Manufacturing\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>494 East Commercial Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Bernardino\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92408\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:killafruitseliquids@gmail.com\"> killafruitseliquids@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:raza@dlymfg.com\"> raza@dlymfg.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 10, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Syed Raza Razavi, Mohammed Shabeer Humkar, and Akbar Ali Razavi:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fkillafruitseliquids.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fkillafruitseliquids.com revealed that you manufacture and offer for sale or distribution to customers in the United States the following e-liquid products without a marketing authorization order including: Killa Fruits E‐ Liquids Kiwi Strawberry Ice and Killa Fruits E‐ Liquids Watermelon Strawberry.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 1,400 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0002389 on September 9, 2020. However, FDA issued a negative action for STN PM0002389 in the form of a Marketing Denial Order determination on October 7, 2021, which covers 180 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by STN PM0002389 that resulted in a Marketing Denial Order determination, are adulterated and misbranded.\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101699, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Ten Days Manufacturing d\u002Fb\u002Fa Daily Manufacturing\u003Cbr>\nAttn: Syed Raza Razavi, Mohammed Shabeer Humkar and Akbar Ali Razavi\u003Cbr>\n458 East Commercial Road\u003Cbr>\nSan Bernardino, CA 92408\u003Cbr>\nkillafruitseliquids.com@wix-domains.com\u003C\u002Fp>\n\n\u003Cp>Network Solutions, LLC\u003Cbr>\nabuse@web.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nSyed Raza Razavi, Mohammed Shabeer Humkar, and Akbar Ali Razavi\n\nTen Days Manufacturing d\u002Fb\u002Fa Daily Manufacturing\n\n494 East Commercial Road\n\nSan Bernardino, CA 92408\n\nUnited States\n\nkillafruitseliquids@gmail.com\n\nraza@dlymfg.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nDecember 10, 2021\n\nWARNING LETTER\n\nDear Syed Raza Razavi, Mohammed Shabeer Humkar, and Akbar Ali Razavi:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fkillafruitseliquids.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fkillafruitseliquids.com revealed that you manufacture and offer for sale or distribution to customers in the United States the following e-liquid products without a marketing authorization order including: Killa Fruits E‐ Liquids Kiwi Strawberry Ice and Killa Fruits E‐ Liquids Watermelon Strawberry.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 1,400 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0002389 on September 9, 2020. However, FDA issued a negative action for STN PM0002389 in the form of a Marketing Denial Order determination on October 7, 2021, which covers 180 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by STN PM0002389 that resulted in a Marketing Denial Order determination, are adulterated and misbranded.\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101699, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nTen Days Manufacturing d\u002Fb\u002Fa Daily Manufacturing\n\nAttn: Syed Raza Razavi, Mohammed Shabeer Humkar and Akbar Ali Razavi\n\n458 East Commercial Road\n\nSan Bernardino, CA 92408\n\nkillafruitseliquids.com@wix-domains.com\n\nNetwork Solutions, LLC\n\nabuse@web.com\n\nShopify, Inc.\n\nabuse@shopify.com","Ten Days Manufacturing d\u002Fb\u002Fa Daily Manufacturing","ten-days-manufacturing-dba-daily-manufacturing-623001-12102021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ften-days-manufacturing-dba-daily-manufacturing-623001-12102021","2026-10-26T08:10:10.438294+00:00","2022-04-05","623001","Syed Raza Razavi, Mohammed Shabeer Humkar, and Akbar Ali Razavi","2026-08-20T02:03:17.364+00:00","2021-12-10",{"id":173,"raw":174,"subject":179,"body_html":180,"body_text":181,"firm_name":182,"letter_id":183,"created_at":184,"fei_number":19,"letter_url":185,"updated_at":186,"action_type":22,"case_status":23,"posted_date":187,"marcs_cms_no":188,"product_type":49,"closeout_date":19,"issuing_office":178,"recipient_name":189,"body_fetched_at":190,"delivery_method":191,"recipient_title":19,"reference_number":19,"action_taken_date":192,"medical_device_id":19,"response_letter_date":19},1179,[175,176,177,178,179,13,13,13],"\u003Ctime datetime=\"2024-11-05T14:20:00Z\">11\u002F05\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-03T04:00:00Z\">06\u002F03\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftop-health-manufacturing-llc-671665-06032024\">Top Health Manufacturing, LLC\u003C\u002Fa>","Division of Human and Animal Food Operations West IV","CGMP\u002FDietary Supplement\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Mathieu Q C Ung, Co-Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Cynthia L. Rudd, Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Top Health Manufacturing, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1350 Calpac Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Spanish Fork\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84660-9298\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 3, 2024&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CMS 671665\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ung and Ms. Rudd:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration, (FDA) conducted an inspection of your dietary supplement manufacturing facility located at 1350 Calpac Avenue, Spanish Fork, UT 84660-9298 on October 12-13, 16, 18, and 20, 2023. Based on inspectional findings and review of the product labels collected during the inspection we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov. &nbsp;\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection on October 20, 2023, you were provided with a Form FDA 483, Inspectional Observations (FDA 483). &nbsp;We acknowledge receipt of your correspondence received on November 10, 2023, and we address your response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility on October 12-13, 16, 18, and 20, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplements Grandma’s Herbs Kidney and \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufactured at your facility to be adulterated within the meaning of Section 402(g)(1) of the Federal Food Drug and Cosmetic Act (the Act) [21 U.S.C. § 342(g)(1)], because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the CGMP requirement area as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not follow written procedures for quality control operations as required by 21 CFR 111.103. Specifically, you do not follow SOP0301-1, \u003Cem>Quality Control Responsibilities\u003C\u002Fem>, (effective date 04\u002F05\u002F2019):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The Master Manufacturing Records (MMRs) for \u003Cstrong>(b)(4)\u003C\u002Fstrong> do not reflect that they approved by your Quality Unit as required by your SOP 0301-0, section 4.1.5.\u003C\u002Fli>\n\t\u003Cli>The Batch Production Records (BPRs) records for \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not approved by the Quality Unit as required by your SOP0301-0, section 4.1.6. In addition, the batch records for \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not reviewed and released by your Quality Unit.\u003C\u002Fli>\n\t\u003Cli>You did not conduct periodic Good Manufacturing (GMP) internal audits of the entire plant with documented corrective actions, as required by your SOP 0301-0, section 4.1.13. An internal audit has not been conducted since 2022.\u003C\u002Fli>\n\t\u003Cli>The calibration logs for scales located in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> rooms were not reviewed by your Quality Unit as required by your SOP 03010, section 4.1.14.\u003C\u002Fli>\n\t\u003Cli>The Quality Unit did not review all laboratory control process and testing results, as required by your SOP 0301-0, section 4.1.16. The finished product testing results for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Grandma’s Herbs Kidney, lot 220107 both analyzed by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were not reviewed by your Quality Unit prior to shipment into interstate &nbsp;commerce.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We have reviewed your response dated November 10, 2023. In your response you state you will retrain your personnel and provide training records to FDA within 30 days. You did not provide any documentation; therefore, we cannot evaluate the implementation.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish required specifications:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You did not establish an identity specification for each component as required by 21 CFR 111.70(b)(1). Specifically, your documents intended to contain component specifications do not contain a specification target or range for “Identification” or indicate a Reference or Method to be used. \u003Cstrong>(b)(4)\u003C\u002Fstrong> (marshmallow) root powder, Juniper berry powder, and Yarrow herb\u002Fflower powder are components in Grandma’s Herbs Kidney. \u003Cstrong>(b)(4)\u003C\u002Fstrong> are components in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. None of these components have a listed specification target, range, reference, or test method. In addition, when asked for component specifications for juniper berry and buchu powder used in Grandma’s Herb Kidney, you stated you did not have any.\u003C\u002Fli>\n\t\u003Cli>You did not establish component specifications for purity and strength as required by 21 CFR 111.70(b)(2). Specifically, your documents intended to contain component specifications do not include target or range for purity or strength. \u003Cstrong>(b)(4)\u003C\u002Fstrong> (marshmallow) root powder, Juniper berry powder, and Yarrow herb\u002Fflower powder are components in Grandma’s Herbs Kidney. \u003Cstrong>(b)(4)\u003C\u002Fstrong> are components in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. None of these components have specifications for purity or strength.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We have reviewed your response dated November 10, 2023. In your response you state you will create specifications for raw materials and that you estimate it will take approximately 90 days. You did not provide any documentation of your specifications, so we cannot evaluate the implementation.\u003C\u002Fp>\n\n\u003Cp>3. You did not establish specifications for the identity, purity, strength, and composition of the finished batch of each dietary supplement you manufacture, as required by 21 CFR 111.70 (e). Specifically, when asked by the FDA investigator, you stated you do not have any finished product specifications for you Grandma’s Herbs Kidney, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary supplement that you manufacture.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated November 10, 2023. In your response you state you will establish specifications for component purity and strengthen within 90 days. You did not provide any documentation, so we cannot evaluate the implementation.\u003C\u002Fp>\n\n\u003Cp>4. You failed to establish MMRs for your products that include all elements required by 21 CFR 111.210. Specifically, the MMR for your products Grandma’s Herbs Kidney and \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed to include the information required by 21 CFR 111.210, such as:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A statement of maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material&nbsp;review is conducted and disposition decision is made, as required by 21 CFR 111.210(f).\u003C\u002Fli>\n\t\u003Cli>Your MMR did not include a description of packaging and a representative &nbsp; label, or a cross-reference to the physical location of the actual or representative label as required by 21 CFR 111.210(g). Specifically, the MMRs for Grandma’s Herbs Kidney, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not include an actual or representative label attached to the MMR or provide a physical location of the actual or representative label.\u003C\u002Fli>\n\t\u003Cli>Written instructions including specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is&nbsp;necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record, as required by 21 CFR 111.210(h)(3). Specifically, your MMR for \u003Cstrong>(b)(4)\u003C\u002Fstrong> does not include instructions for capsule drying or packaging operations. In addition, the MMR does not contain detailed&nbsp;instructions for the encapsulation process.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We have reviewed your response dated November 10, 2023. In your response you state you will revise your MMRs and update FDA on your progress in 30 business days. You did not provide any documentation, so we cannot evaluate the implementation.\u003C\u002Fp>\n\n\u003Cp>5. Your batch production record did not include complete information relating to the production and control of each batch as required by 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, your batch records for Grandma’s Herbs Kidney and \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed to include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross reference to&nbsp;records where this information is retained (Grandma’s Herb Kidney preweigh, lots C230915 and C220101, Grandma’s Herbs Kidney encapsulation, lots E230902 and E220101, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> as required by 21 CFR 11.260(c).\u003C\u002Fli>\n\t\u003Cli>Statement of the percentage of theoretical yield at appropriate phases of&nbsp;processing (Grandma’s Herbs Kidney Encapsulation, lots E220101 and E230902, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) as required by 21 CFR 111.260(f).\u003C\u002Fli>\n\t\u003Cli>The date on which each step of the master manufacturing record was performed, (Grandma’s Herbs Kidney pre-weigh, lots C220202 and C230914 and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> as required by 111.260(j)(1).&nbsp;\u003C\u002Fli>\n\t\u003Cli>Documentation of packaging operations for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as required by 21 CFR 111.260(k).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We have reviewed your response dated November 10, 2023. In your response you state you will update your batch production and update FDA on your progress in 30 business days. You did not provide any documentation, so we cannot evaluate the implementation.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>In addition, we reviewed your products labels collected during the inspection and have determined the Grandma’s Herbs Kidney and \u003Cstrong>(b)(4)\u003C\u002Fstrong> products you manufacture are misbranded under section 403 of the Act [21 U.S.C. &nbsp;343] because they do not comply with the labeling requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. The Grandma’s Herbs Kidney product is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. &nbsp;§ 343(s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1). Specifically, you list the ingredients parsley, cleavers, and meadowsweet as “herb” and do not identify the plant part used in the product. If the whole or entire plant is used, that information must be listed.\u003C\u002Fp>\n\n\u003Cp>2. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> product is misbranded within the meaning of section 403(a)(1) of the Act [21 U.S.C. § 343(a)(1)] in that the labeling is false or misleading. The product label identifies the ingredient “candelilla wax”, but the batch record reviewed during the inspection for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, shows that candelilla wax was not added to the product despite the declaration on the label. &nbsp;\u003C\u002Fp>\n\n\u003Cp>3. The Grandma’s Herbs Kidney and \u003Cstrong>(b)(4)\u003C\u002Fstrong> products are misbranded under 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] because the presentation of the nutrition information on the labeling of each product label does not comply with 21 CFR 101.36 and 21 CFR 101.9. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp;- Grandma’s Herbs Kidney\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. The product label does not list the quantitative weight of the proprietary blend using the appropriate units, which is not in accordance with 21 CFR 101.36(b)(3)(ii)(A).\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. The dietary ingredients of the proprietary blend do not appear to be indented, which is not in accordance with 21 CFR 101.36(c)(2).&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; iii. The nutrition information is not presented using a uniform type size, which is not in accordance with 21 CFR 101.36(e). In addition, the heading “%Daily Value” fails to be bolded.\u003C\u002Fp>\n\n\u003Cp>&nbsp;-&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. The product label does not have a heavy bar under the final (b)(2)-dietary ingredient, which is not in accordance with 21 CFR 101.36(e)(6)(ii).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We also have the following comment:\u003C\u002Fp>\n\n\u003Cp>The Grandma’s Herbs Kidney product label declares “Allergy warning: Manufactured in facility that also handles milk, eggs, fish, shellfish, tree nuts, peanuts, wheat and soybean.” Advisory labeling is not a substitute for adherence to current good manufacturing practices and, when used by a facility, food allergen preventive controls. See Guidance for Industry: Questions and Answers Regarding Food Allergens Labeling, (Edition 5) (https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidancedocuments\u002Fguidance-industry-questions-and-answers-regarding-food-allergenlabeling-edition-5). The firm should make every effort to ensure that they and their suppliers have adequate GMPs in place to prevent the unintentional inclusion of allergens in their products and ingredients.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within 15 working days of the receipt of this letter of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent recurrence of the violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen (15) working days of the receipt of this letter as to the specific steps you have taken to correct the stated violations, including an explanation of each step being taken to identify violations and make corrections to ensure that similar violations will not recur. In your response, you should include documentation, including revised procedures. Photographic, results of tests you have conducted, and other useful information that would assist us in evaluating your corrections.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to Director of Compliance Branch Jennifer Hicks at U.S. Food and Drug Administration, DFC Bldg 20 – W. 6th Ave &amp; Kipling St., P.O. Box 25087, Denver, CO 80225. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have questions regarding this letter, please contact Jennifer Hicks by telephone at (303) 503-9289 or by email at jennifer.hicks@fda.hhs.gov. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nE. Mark Harris\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Foods-\u003Cbr>\nWest Division 4&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nMr. Mathieu Q C Ung, Co-Owner\n\nRecipient Title\n\nMs. Cynthia L. Rudd, Co-Owner\n\nTop Health Manufacturing, LLC\n\n1350 Calpac Avenue\n\nSpanish Fork, UT 84660-9298\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West IV\n\nUnited States\n\nJune 3, 2024\n\nWARNING LETTER\n\nCMS 671665\n\nDear Mr. Ung and Ms. Rudd:\n\nThe U.S. Food and Drug Administration, (FDA) conducted an inspection of your dietary supplement manufacturing facility located at 1350 Calpac Avenue, Spanish Fork, UT 84660-9298 on October 12-13, 16, 18, and 20, 2023. Based on inspectional findings and review of the product labels collected during the inspection we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\n\nAt the conclusion of the inspection on October 20, 2023, you were provided with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your correspondence received on November 10, 2023, and we address your response below, in relation to each of the noted violations.\n\nAdulterated Dietary Supplements\n\nThe inspection of your facility on October 12-13, 16, 18, and 20, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplements Grandma’s Herbs Kidney and (b)(4) manufactured at your facility to be adulterated within the meaning of Section 402(g)(1) of the Federal Food Drug and Cosmetic Act (the Act) [21 U.S.C. § 342(g)(1)], because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\n\nYour significant violations of the CGMP requirement area as follows:\n\n1. You did not follow written procedures for quality control operations as required by 21 CFR 111.103. Specifically, you do not follow SOP0301-1, Quality Control Responsibilities, (effective date 04\u002F05\u002F2019):\n\nThe Master Manufacturing Records (MMRs) for (b)(4) do not reflect that they approved by your Quality Unit as required by your SOP 0301-0, section 4.1.5.\n\nThe Batch Production Records (BPRs) records for (b)(4) were not approved by the Quality Unit as required by your SOP0301-0, section 4.1.6. In addition, the batch records for (b)(4) were not reviewed and released by your Quality Unit.\n\nYou did not conduct periodic Good Manufacturing (GMP) internal audits of the entire plant with documented corrective actions, as required by your SOP 0301-0, section 4.1.13. An internal audit has not been conducted since 2022.\n\nThe calibration logs for scales located in the (b)(4) and (b)(4) rooms were not reviewed by your Quality Unit as required by your SOP 03010, section 4.1.14.\n\nThe Quality Unit did not review all laboratory control process and testing results, as required by your SOP 0301-0, section 4.1.16. The finished product testing results for (b)(4), and Grandma’s Herbs Kidney, lot 220107 both analyzed by (b)(4), were not reviewed by your Quality Unit prior to shipment into interstate commerce.\n\nWe have reviewed your response dated November 10, 2023. In your response you state you will retrain your personnel and provide training records to FDA within 30 days. You did not provide any documentation; therefore, we cannot evaluate the implementation.\n\n2. You failed to establish required specifications:\n\nYou did not establish an identity specification for each component as required by 21 CFR 111.70(b)(1). Specifically, your documents intended to contain component specifications do not contain a specification target or range for “Identification” or indicate a Reference or Method to be used. (b)(4) (marshmallow) root powder, Juniper berry powder, and Yarrow herb\u002Fflower powder are components in Grandma’s Herbs Kidney. (b)(4) are components in (b)(4). None of these components have a listed specification target, range, reference, or test method. In addition, when asked for component specifications for juniper berry and buchu powder used in Grandma’s Herb Kidney, you stated you did not have any.\n\nYou did not establish component specifications for purity and strength as required by 21 CFR 111.70(b)(2). Specifically, your documents intended to contain component specifications do not include target or range for purity or strength. (b)(4) (marshmallow) root powder, Juniper berry powder, and Yarrow herb\u002Fflower powder are components in Grandma’s Herbs Kidney. (b)(4) are components in (b)(4). None of these components have specifications for purity or strength.\n\nWe have reviewed your response dated November 10, 2023. In your response you state you will create specifications for raw materials and that you estimate it will take approximately 90 days. You did not provide any documentation of your specifications, so we cannot evaluate the implementation.\n\n3. You did not establish specifications for the identity, purity, strength, and composition of the finished batch of each dietary supplement you manufacture, as required by 21 CFR 111.70 (e). Specifically, when asked by the FDA investigator, you stated you do not have any finished product specifications for you Grandma’s Herbs Kidney, and (b)(4) dietary supplement that you manufacture.\n\nWe have reviewed your response dated November 10, 2023. In your response you state you will establish specifications for component purity and strengthen within 90 days. You did not provide any documentation, so we cannot evaluate the implementation.\n\n4. You failed to establish MMRs for your products that include all elements required by 21 CFR 111.210. Specifically, the MMR for your products Grandma’s Herbs Kidney and (b)(4) failed to include the information required by 21 CFR 111.210, such as:\n\nA statement of maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made, as required by 21 CFR 111.210(f).\n\nYour MMR did not include a description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label as required by 21 CFR 111.210(g). Specifically, the MMRs for Grandma’s Herbs Kidney, and (b)(4) did not include an actual or representative label attached to the MMR or provide a physical location of the actual or representative label.\n\nWritten instructions including specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record, as required by 21 CFR 111.210(h)(3). Specifically, your MMR for (b)(4) does not include instructions for capsule drying or packaging operations. In addition, the MMR does not contain detailed instructions for the encapsulation process.\n\nWe have reviewed your response dated November 10, 2023. In your response you state you will revise your MMRs and update FDA on your progress in 30 business days. You did not provide any documentation, so we cannot evaluate the implementation.\n\n5. Your batch production record did not include complete information relating to the production and control of each batch as required by 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, your batch records for Grandma’s Herbs Kidney and (b)(4) failed to include:\n\nDate and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross reference to records where this information is retained (Grandma’s Herb Kidney preweigh, lots C230915 and C220101, Grandma’s Herbs Kidney encapsulation, lots E230902 and E220101, (b)(4), lot (b)(4), (b)(4), lot (b)(4), and (b)(4) lot (b)(4) as required by 21 CFR 11.260(c).\n\nStatement of the percentage of theoretical yield at appropriate phases of processing (Grandma’s Herbs Kidney Encapsulation, lots E220101 and E230902, (b)(4), lot (b)(4), and (b)(4), lot (b)(4)) as required by 21 CFR 111.260(f).\n\nThe date on which each step of the master manufacturing record was performed, (Grandma’s Herbs Kidney pre-weigh, lots C220202 and C230914 and (b)(4), lot (b)(4) as required by 111.260(j)(1).\n\nDocumentation of packaging operations for (b)(4), lot (b)(4), as required by 21 CFR 111.260(k).\n\nWe have reviewed your response dated November 10, 2023. In your response you state you will update your batch production and update FDA on your progress in 30 business days. You did not provide any documentation, so we cannot evaluate the implementation.\n\nMisbranded Dietary Supplements\n\nIn addition, we reviewed your products labels collected during the inspection and have determined the Grandma’s Herbs Kidney and (b)(4) products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements.\n\nSpecifically, we identified the following:\n\n1. The Grandma’s Herbs Kidney product is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1). Specifically, you list the ingredients parsley, cleavers, and meadowsweet as “herb” and do not identify the plant part used in the product. If the whole or entire plant is used, that information must be listed.\n\n2. The (b)(4) product is misbranded within the meaning of section 403(a)(1) of the Act [21 U.S.C. § 343(a)(1)] in that the labeling is false or misleading. The product label identifies the ingredient “candelilla wax”, but the batch record reviewed during the inspection for (b)(4), shows that candelilla wax was not added to the product despite the declaration on the label.\n\n3. The Grandma’s Herbs Kidney and (b)(4) products are misbranded under 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] because the presentation of the nutrition information on the labeling of each product label does not comply with 21 CFR 101.36 and 21 CFR 101.9. For example:\n\n- Grandma’s Herbs Kidney\n\ni. The product label does not list the quantitative weight of the proprietary blend using the appropriate units, which is not in accordance with 21 CFR 101.36(b)(3)(ii)(A).\n\nii. The dietary ingredients of the proprietary blend do not appear to be indented, which is not in accordance with 21 CFR 101.36(c)(2).\n\niii. The nutrition information is not presented using a uniform type size, which is not in accordance with 21 CFR 101.36(e). In addition, the heading “%Daily Value” fails to be bolded.\n\n- (b)(4)\n\ni. The product label does not have a heavy bar under the final (b)(2)-dietary ingredient, which is not in accordance with 21 CFR 101.36(e)(6)(ii).\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe also have the following comment:\n\nThe Grandma’s Herbs Kidney product label declares “Allergy warning: Manufactured in facility that also handles milk, eggs, fish, shellfish, tree nuts, peanuts, wheat and soybean.” Advisory labeling is not a substitute for adherence to current good manufacturing practices and, when used by a facility, food allergen preventive controls. See Guidance for Industry: Questions and Answers Regarding Food Allergens Labeling, (Edition 5) (https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidancedocuments\u002Fguidance-industry-questions-and-answers-regarding-food-allergenlabeling-edition-5). The firm should make every effort to ensure that they and their suppliers have adequate GMPs in place to prevent the unintentional inclusion of allergens in their products and ingredients.\n\nPlease notify this office in writing within 15 working days of the receipt of this letter of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent recurrence of the violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease notify this office in writing within fifteen (15) working days of the receipt of this letter as to the specific steps you have taken to correct the stated violations, including an explanation of each step being taken to identify violations and make corrections to ensure that similar violations will not recur. In your response, you should include documentation, including revised procedures. Photographic, results of tests you have conducted, and other useful information that would assist us in evaluating your corrections.\n\nYour written response should be sent to Director of Compliance Branch Jennifer Hicks at U.S. Food and Drug Administration, DFC Bldg 20 – W. 6th Ave & Kipling St., P.O. Box 25087, Denver, CO 80225. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have questions regarding this letter, please contact Jennifer Hicks by telephone at (303) 503-9289 or by email at jennifer.hicks@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nProgram Division Director\n\nOffice of Human and Animal Foods-\n\nWest Division 4","Top Health Manufacturing, LLC","top-health-manufacturing-llc-671665-06032024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftop-health-manufacturing-llc-671665-06032024","2026-10-26T08:10:13.747674+00:00","2024-11-05","671665","Mr. Mathieu Q C Ung, Co-Owner","2026-08-19T19:15:10.412+00:00","VIA UPS","2024-06-03",{"id":194,"raw":195,"subject":122,"body_html":199,"body_text":200,"firm_name":201,"letter_id":202,"created_at":203,"fei_number":19,"letter_url":204,"updated_at":205,"action_type":22,"case_status":23,"posted_date":206,"marcs_cms_no":207,"product_type":131,"closeout_date":19,"issuing_office":121,"recipient_name":208,"body_fetched_at":209,"delivery_method":133,"recipient_title":19,"reference_number":19,"action_taken_date":206,"medical_device_id":19,"response_letter_date":19},3020,[196,197,198,121,122,13,13,13],"\u003Ctime datetime=\"2021-11-19T16:00:00Z\">11\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-19T05:00:00Z\">11\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fuis-manufacturing-llc-dba-uis-vapes-621452-11192021\">UIS Manufacturing, LLC d\u002Fb\u002Fa UIS Vapes\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sean Slane\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>UIS Manufacturing, LLC d\u002Fb\u002Fa UIS Vapes\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>128 North Center Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Somerset\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>15501\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sean@uisvapes.com\"> sean@uisvapes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 19, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Slane:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that UIS Manufacturing, LLC d\u002Fb\u002Fa UIS Vapes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: UIS Vapes Apple Jacks 3mg 30 ML, UIS Vapes Jolly Green 3mg 30ML, and UIS Vapes Dark Matter 3mg 30ML.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 400 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0002774, on September 8, 2020. However, FDA issued a negative action for STN PM0002774 in the form of a Marketing Denial Order determination on September 14, 2021, which covers 320 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0002774 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100328, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nSean Slane\n\nRecipient Title\n\nOwner\n\nUIS Manufacturing, LLC d\u002Fb\u002Fa UIS Vapes\n\n128 North Center Avenue\n\nSomerset, PA 15501\n\nUnited States\n\nsean@uisvapes.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 19, 2021\n\nWARNING LETTER\n\nDear Mr. Slane:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that UIS Manufacturing, LLC d\u002Fb\u002Fa UIS Vapes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: UIS Vapes Apple Jacks 3mg 30 ML, UIS Vapes Jolly Green 3mg 30ML, and UIS Vapes Dark Matter 3mg 30ML.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 400 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0002774, on September 8, 2020. However, FDA issued a negative action for STN PM0002774 in the form of a Marketing Denial Order determination on September 14, 2021, which covers 320 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0002774 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100328, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","UIS Manufacturing, LLC d\u002Fb\u002Fa UIS Vapes","uis-manufacturing-llc-dba-uis-vapes-621452-11192021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fuis-manufacturing-llc-dba-uis-vapes-621452-11192021","2026-10-26T08:10:16.754019+00:00","2021-11-19","621452","Sean Slane","2026-08-20T02:26:01.573+00:00",{"id":211,"raw":212,"subject":12,"body_html":216,"body_text":217,"firm_name":218,"letter_id":219,"created_at":18,"fei_number":19,"letter_url":220,"updated_at":221,"action_type":22,"case_status":23,"posted_date":222,"marcs_cms_no":223,"product_type":70,"closeout_date":19,"issuing_office":11,"recipient_name":224,"body_fetched_at":225,"delivery_method":226,"recipient_title":19,"reference_number":227,"action_taken_date":228,"medical_device_id":19,"response_letter_date":19},380,[213,214,215,11,12,13,13,13],"\u003Ctime datetime=\"2026-01-06T05:00:00Z\">01\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-19T05:00:00Z\">12\u002F19\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fliquidcapsule-manufacturing-llc-717069-12192025\">LiquidCapsule Manufacturing, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>Return Receipt Requested\n                                                                          \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-31\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Frederick H. Miller\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>LiquidCapsule Manufacturing, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9216 Palm River Road, Suite 203\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tampa\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33619-4478\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-26-31\u003C\u002Fp>\u003Cp>December 19, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Miller:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, LiquidCapsule Manufacturing, LLC, FEI 3006676534, at 9216 Palm River Road, Suite 203, Tampa, Florida, from June 25 to July 3, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your July 25, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to conduct adequate identity testing on incoming components used in the manufacture of your over-the-counter (OTC) drug products. For example, you failed to adequately test each shipment of each lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>See FDA’s guidance for industry \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Identity testing for the high-risk drug component \u003Cstrong>(b)(4)\u003C\u002Fstrong> includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because you did not perform adequate identity testing using the USP identification test that detects this hazardous impurity, you failed to ensure the acceptability of the component for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>Additionally, you relied on your suppliers’ Certificates of Analysis (COAs) without establishing the reliability of each of your component supplier’s test analysis at appropriate intervals.\u003C\u002Fp>\u003Cp>In your response, you state that you will establish or revise raw material specification sheets for appropriate comprehensive testing of all incoming materials, and you will review your program for periodically validating supplier COAs for all raw materials.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not provide sufficient details to ensure adequate remediation of your incoming materials testing program, and it lacks a retrospective review, analysis, and risk assessment for previously distributed drug products that are within expiry.\u003C\u002Fp>\u003Cp>Without adequate testing and confirmation of the reliability of supplier test results, you lack scientific evidence that the components used in your drug products conform to appropriate specifications before their use in the drug products you manufacture.\u003C\u002Fp>\u003Cp>In response to this letter, please provide a comprehensive, independent review of your material system, including but not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct the specific identity tests for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to demonstrate that your test methods were appropriate to assure that your product conforms to appropriate standards of identity, strength, quality, and purity. For example, your firm performs assay for \u003Cstrong>(b)(4)\u003C\u002Fstrong> using a \u003Cstrong>(b)(4)\u003C\u002Fstrong> method. The data you provided to support equivalency of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> method to the USP compendial method consisted of assay results for \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot of material tested by \u003Cstrong>(b)(4)\u003C\u002Fstrong> third-party laboratories. A protocol or report describing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> method and its validated state, or criteria for determining its equivalency with the USP method, was not provided. Additionally, you have not adequately qualified the third-party laboratories used to perform your analysis.\u003C\u002Fp>\u003Cp>In your response, you stated that you would cease use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> method until its equivalence to the compendial method is scientifically demonstrated.\u003C\u002Fp>\u003Cp>Your response is inadequate because it did not evaluate the distributed batches on which you used the \u003Cstrong>(b)(4)\u003C\u002Fstrong> method for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> assay test.\u003C\u002Fp>\u003Cp>Test methods must be validated to show that they are suitable for their intended use and are equivalent to or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications.\u003C\u002Fp>\u003Cp>In response to this letter, please provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>The method validation protocol, report, and supporting data for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> assay method, and any revised methods. Include the scientific rationale for its use as release and stability indicating tests.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm does not have an adequate stability testing program to demonstrate that the chemical and microbiological properties of your drug products meet established specifications, and that they remain acceptable for the duration of their labeled shelf lives \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, you failed to revise the SOP for your stability program, issued March 23, 2020, as you previously committed to do, and the procedure does not address ongoing stability testing to monitor your drug’s quality attributes throughout its shelf life.\u003C\u002Fp>\u003Cp>Without an appropriate stability program, you lack adequate scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through your labeled expiry.\u003C\u002Fp>\u003Cp>In your response, you stated that you will segregate and identify stability samples from retain samples for each manufactured batch, and that you will conduct a thorough inventory and assessment of all existing retain samples to identify batches requiring immediate stability evaluation.\u003C\u002Fp>\u003Cp>Your response is inadequate because you did not provide suitable justification that the selection of retain samples is adequate to support all existing distributed batches through labeled expiry.\u003C\u002Fp>\u003Cp>In response to this letter, please provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to ensure that batch records are complete, and that all manufacturing activities and operations are recorded contemporaneously.\u003C\u002Fp>\u003Cp>For example, the batch record for batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufactured in December 2024, approximately 6 months before the inspection, did not contain complete information including the full results of in-process testing, and shows multiple instances where initials and dates were pre-filled without documentation of performance, or evidence of performance. Information provided by your firm for batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicates that this batch was distributed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, although the “QA Checklist” for batch record review and release was not completed.\u003C\u002Fp>\u003Cp>In your response, you state that you conducted a review of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch production records to identify any other similar documentation omissions or discrepancies and to assess their potential impact on product quality or safety.\u003C\u002Fp>\u003Cp>Your response is inadequate because you did not expand your review to all drug products, in individual configurations, for lots previously distributed and within expiry. You also did not include an investigation to determine the root cause of the incomplete documentation or assess the impact on finished batches.\u003C\u002Fp>\u003Cp>Complete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and are reproducible. Additionally, incomplete manufacturing records deprive you of the ability to reliably conduct batch record review, to adequately investigate deviations and batch failures, and to ensure a continued state of validation processes.\u003C\u002Fp>\u003Cp>In response to this letter, please provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient.\u003C\u002Fli>\u003Cli>A detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>5. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Process System Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm failed to adequately validate the manufacturing process for your drug products. The validation data provided from 2017 does not include the filling and packaging of your drug product into the final containers. You had previously committed to providing a retrospective validation report; however, to date there does not appear to be any evaluation or documentation establishing equivalency between your validation data from 2017 and your current manufacturing process, including the difference in batch size.\u003C\u002Fp>\u003Cp>In your response, you stated that you would retrospectively assess the 2017 bulk manufacturing process validation and evaluate its adequacy, considering current understanding and practices. You also stated that you would perform prospective process validation for each OTC drug product.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not address the absence of validation for the filling and packaging process and lacks details regarding your prospective process validation plan.\u003C\u002Fp>\u003Cp>In response to this letter, please provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cem>Lack of \u003Cstrong>(b)(4)\u003C\u002Fstrong> System Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately validate your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system to ensure it produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets appropriate chemical and microbial attributes for use in your OTC drug product manufacturing. In addition, you failed to demonstrate that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system was adequately monitored to ensure it consistently produced \u003Cstrong>(b)(4)\u003C\u002Fstrong> that met appropriate chemical and microbial quality standards. For example, you failed to conduct \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, and you did not monitor your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system for \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex (BCC).\u003C\u002Fp>\u003Cp>Furthermore, the COAs you provided for routine testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples show that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> is tested according to standard methods for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and that the specifications listed on the COAs do not match those required by your SOP “MPC-5005 Rev 1 \u003Cstrong>(b)(4)\u003C\u002Fstrong> System Monitoring, Testing, and Usage.” For example, the COA requires a total plate count &lt;\u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fg; however, your SOP specifies the acceptable range for total plate count as \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fg – \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fg.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts, with appropriate specifications, and identity of contamination in the system is integral to ensuring oversight of the ongoing state of control and the suitability of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for use in manufacturing operations.\u003C\u002Fp>\u003Cp>In your response, you state that you have initiated a comprehensive validation study of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system and will revise procedures for monitoring to include appropriate chemical and microbiological testing, including for \u003Cem>Burkholderia cepacia\u003C\u002Fem> Complex (BCC).\u003C\u002Fp>\u003Cp>Your response is inadequate because you did not provide the details of your validation study or the revised procedures and specifications for routine monitoring or usage.\u003C\u002Fp>\u003Cp>In response to this letter, please provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies adequate, routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The current limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a previous inspection, dated February 5 to February 9, 2024, FDA cited similar CGMP observations. Following a July 2024 regulatory meeting, you proposed specific remediation to your stability program. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3006676534 and ATTN: Maria Pavco.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReturn Receipt Requested\n\nReference #:\n\n320-26-31\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Frederick H. Miller\n\nRecipient Title\n\nPresident\n\nLiquidCapsule Manufacturing, LLC\n\n9216 Palm River Road, Suite 203\n\nTampa, FL 33619-4478\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-31\nDecember 19, 2025\nDear Mr. Miller:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, LiquidCapsule Manufacturing, LLC, FEI 3006676534, at 9216 Palm River Road, Suite 203, Tampa, Florida, from June 25 to July 3, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your July 25, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou failed to conduct adequate identity testing on incoming components used in the manufacture of your over-the-counter (OTC) drug products. For example, you failed to adequately test each shipment of each lot of (b)(4) for (b)(4).\nSee FDA’s guidance for industry (b)(4).\nIdentity testing for the high-risk drug component (b)(4) includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for (b)(4). Because you did not perform adequate identity testing using the USP identification test that detects this hazardous impurity, you failed to ensure the acceptability of the component for use in the manufacture of your drug products.\nAdditionally, you relied on your suppliers’ Certificates of Analysis (COAs) without establishing the reliability of each of your component supplier’s test analysis at appropriate intervals.\nIn your response, you state that you will establish or revise raw material specification sheets for appropriate comprehensive testing of all incoming materials, and you will review your program for periodically validating supplier COAs for all raw materials.\nYour response is inadequate because it does not provide sufficient details to ensure adequate remediation of your incoming materials testing program, and it lacks a retrospective review, analysis, and risk assessment for previously distributed drug products that are within expiry.\nWithout adequate testing and confirmation of the reliability of supplier test results, you lack scientific evidence that the components used in your drug products conform to appropriate specifications before their use in the drug products you manufacture.\nIn response to this letter, please provide a comprehensive, independent review of your material system, including but not limited to:\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct the specific identity tests for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nYour firm failed to demonstrate that your test methods were appropriate to assure that your product conforms to appropriate standards of identity, strength, quality, and purity. For example, your firm performs assay for (b)(4) using a (b)(4) method. The data you provided to support equivalency of the (b)(4) method to the USP compendial method consisted of assay results for (b)(4) lot of material tested by (b)(4) third-party laboratories. A protocol or report describing the (b)(4) method and its validated state, or criteria for determining its equivalency with the USP method, was not provided. Additionally, you have not adequately qualified the third-party laboratories used to perform your analysis.\nIn your response, you stated that you would cease use of the (b)(4) method until its equivalence to the compendial method is scientifically demonstrated.\nYour response is inadequate because it did not evaluate the distributed batches on which you used the (b)(4) method for your (b)(4) assay test.\nTest methods must be validated to show that they are suitable for their intended use and are equivalent to or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications.\nIn response to this letter, please provide the following:\nThe method validation protocol, report, and supporting data for your (b)(4) assay method, and any revised methods. Include the scientific rationale for its use as release and stability indicating tests.\nA comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\nYour firm does not have an adequate stability testing program to demonstrate that the chemical and microbiological properties of your drug products meet established specifications, and that they remain acceptable for the duration of their labeled shelf lives (b)(4). For example, you failed to revise the SOP for your stability program, issued March 23, 2020, as you previously committed to do, and the procedure does not address ongoing stability testing to monitor your drug’s quality attributes throughout its shelf life.\nWithout an appropriate stability program, you lack adequate scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through your labeled expiry.\nIn your response, you stated that you will segregate and identify stability samples from retain samples for each manufactured batch, and that you will conduct a thorough inventory and assessment of all existing retain samples to identify batches requiring immediate stability evaluation.\nYour response is inadequate because you did not provide suitable justification that the selection of retain samples is adequate to support all existing distributed batches through labeled expiry.\nIn response to this letter, please provide the following:\nA comprehensive assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint)\nAll procedures that describe these and other elements of your remediated stability program.\n4. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\nYou failed to ensure that batch records are complete, and that all manufacturing activities and operations are recorded contemporaneously.\nFor example, the batch record for batch (b)(4), manufactured in December 2024, approximately 6 months before the inspection, did not contain complete information including the full results of in-process testing, and shows multiple instances where initials and dates were pre-filled without documentation of performance, or evidence of performance. Information provided by your firm for batch (b)(4) indicates that this batch was distributed on (b)(4), although the “QA Checklist” for batch record review and release was not completed.\nIn your response, you state that you conducted a review of the (b)(4) batch production records to identify any other similar documentation omissions or discrepancies and to assess their potential impact on product quality or safety.\nYour response is inadequate because you did not expand your review to all drug products, in individual configurations, for lots previously distributed and within expiry. You also did not include an investigation to determine the root cause of the incomplete documentation or assess the impact on finished batches.\nComplete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and are reproducible. Additionally, incomplete manufacturing records deprive you of the ability to reliably conduct batch record review, to adequately investigate deviations and batch failures, and to ensure a continued state of validation processes.\nIn response to this letter, please provide the following:\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient.\nA detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n5. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nInadequate Process System Validation\nYour firm failed to adequately validate the manufacturing process for your drug products. The validation data provided from 2017 does not include the filling and packaging of your drug product into the final containers. You had previously committed to providing a retrospective validation report; however, to date there does not appear to be any evaluation or documentation establishing equivalency between your validation data from 2017 and your current manufacturing process, including the difference in batch size.\nIn your response, you stated that you would retrospectively assess the 2017 bulk manufacturing process validation and evaluate its adequacy, considering current understanding and practices. You also stated that you would perform prospective process validation for each OTC drug product.\nYour response is inadequate because it does not address the absence of validation for the filling and packaging process and lacks details regarding your prospective process validation plan.\nIn response to this letter, please provide the following:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nLack of (b)(4) System Validation\nYou failed to adequately validate your (b)(4) system to ensure it produces (b)(4) that meets appropriate chemical and microbial attributes for use in your OTC drug product manufacturing. In addition, you failed to demonstrate that your (b)(4) system was adequately monitored to ensure it consistently produced (b)(4) that met appropriate chemical and microbial quality standards. For example, you failed to conduct (b)(4) testing, and you did not monitor your (b)(4) system for Burkholderia cepacia complex (BCC).\nFurthermore, the COAs you provided for routine testing of (b)(4) samples show that your (b)(4) is tested according to standard methods for (b)(4), and that the specifications listed on the COAs do not match those required by your SOP “MPC-5005 Rev 1 (b)(4) System Monitoring, Testing, and Usage.” For example, the COA requires a total plate count \u003C(b)(4) cfu\u002Fg; however, your SOP specifies the acceptable range for total plate count as (b)(4) cfu\u002Fg – (b)(4) cfu\u002Fg.\n(b)(4) must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts, with appropriate specifications, and identity of contamination in the system is integral to ensuring oversight of the ongoing state of control and the suitability of (b)(4) for use in manufacturing operations.\nIn your response, you state that you have initiated a comprehensive validation study of the (b)(4) system and will revise procedures for monitoring to include appropriate chemical and microbiological testing, including for Burkholderia cepacia Complex (BCC).\nYour response is inadequate because you did not provide the details of your validation study or the revised procedures and specifications for routine monitoring or usage.\nIn response to this letter, please provide the following:\nA procedure for your (b)(4) system monitoring that specifies adequate, routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe current limits for total counts and objectionable organisms used for your (b)(4) system. Ensure that the total count limits for your (b)(4) are appropriately stringent in view of the intended use of each of the products produced by your firm.\nRepeat Observations at Facility\nIn a previous inspection, dated February 5 to February 9, 2024, FDA cited similar CGMP observations. Following a July 2024 regulatory meeting, you proposed specific remediation to your stability program. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nQuality Systems\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCGMP Consultant Recommended\nBecause you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3006676534 and ATTN: Maria Pavco.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","LiquidCapsule Manufacturing, LLC","liquidcapsule-manufacturing-llc-717069-12192025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fliquidcapsule-manufacturing-llc-717069-12192025","2026-10-26T08:09:15.183116+00:00","2026-01-06","717069","Mr. Frederick H. Miller","2026-08-19T07:18:39.952+00:00","Via Email Return Receipt Requested","320-26-31","2025-12-19",{"id":230,"raw":231,"subject":236,"body_html":237,"body_text":238,"firm_name":239,"letter_id":240,"created_at":184,"fei_number":19,"letter_url":241,"updated_at":242,"action_type":22,"case_status":23,"posted_date":243,"marcs_cms_no":244,"product_type":26,"closeout_date":19,"issuing_office":235,"recipient_name":245,"body_fetched_at":246,"delivery_method":247,"recipient_title":19,"reference_number":19,"action_taken_date":243,"medical_device_id":19,"response_letter_date":19},1396,[232,233,234,235,236,13,13,13],"\u003Ctime datetime=\"2024-07-02T13:20:00Z\">07\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-02T04:00:00Z\">07\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremier-manufacturing-products-llc-678912-07022024\">Premier Manufacturing Products, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>Atofil@mtdst.us\n                                                                          \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James P. Morrissette\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Premier Manufacturing Products, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>912 46th Lane Unit 204\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cape Coral\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33904\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:JPM@premiermt.com\"> JPM@premiermt.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 2, 2024\u003Cbr>\n\u003Cbr>\nChristopher Mitchell, COO\u003Cbr>\nIT@MTDST.US\u003Cbr>\nCSM@premierMT.com\u003C\u002Fp>\n\n\u003Cp>Deborah L. Lloyd\u003Cbr>\nPremier Manufacturing Products, LLC\u003Cbr>\n730 NE 19th Place,\u003Cbr>\nCape Coral, FL 33909\u003Cbr>\nDlloyd@atofil.us\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 678912\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear James Morrissette, Christopher Mitchell and Deborah Lloyd:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed labeling obtained from an inspection of your drug manufacturing facility, Atofil, LLC, from January 22 to 25, 2024, from which FDA observed that you offer numerous Tianeptine products, specifically “Tianaa Red,” “Tianaa White,” and “Tianaa Green” for sale in the United States. Based on our review, your “Tianaa Red,” “Tianaa White,” and “Tianaa Green” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on our review of the product labeling obtained during the inspection, your “Tianaa Red,” “Tianaa White,” and “Tianaa Green” products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your email blast promotional material, which links back to your website https:\u002F\u002Fmtbrands.com\u002Ftianaa, that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“The Wait For Tianaa is Over . . . LET US TAKE YOU THERE . . . Tianaa is a proprietary blend of Natural Herbs and Nootropics created to deliver the unparalleled pick up, clarity, relaxation, and relief”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your “Tianaa Red,” “Tianaa White,” and “Tianaa Green” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTina Smith, M.S.\u003Cbr>\nCaptain, U.S Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nAtofil@mtdst.us\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJames P. Morrissette\n\nRecipient Title\n\nCEO\n\nPremier Manufacturing Products, LLC\n\n912 46th Lane Unit 204\n\nCape Coral, FL 33904\n\nUnited States\n\nJPM@premiermt.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nJuly 2, 2024\n\nChristopher Mitchell, COO\n\nIT@MTDST.US\n\nCSM@premierMT.com\n\nDeborah L. Lloyd\n\nPremier Manufacturing Products, LLC\n\n730 NE 19th Place,\n\nCape Coral, FL 33909\n\nDlloyd@atofil.us\n\nRE: 678912\n\nDear James Morrissette, Christopher Mitchell and Deborah Lloyd:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed labeling obtained from an inspection of your drug manufacturing facility, Atofil, LLC, from January 22 to 25, 2024, from which FDA observed that you offer numerous Tianeptine products, specifically “Tianaa Red,” “Tianaa White,” and “Tianaa Green” for sale in the United States. Based on our review, your “Tianaa Red,” “Tianaa White,” and “Tianaa Green” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nUnapproved New Drugs\n\nBased on our review of the product labeling obtained during the inspection, your “Tianaa Red,” “Tianaa White,” and “Tianaa Green” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims from your email blast promotional material, which links back to your website https:\u002F\u002Fmtbrands.com\u002Ftianaa, that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\n“The Wait For Tianaa is Over . . . LET US TAKE YOU THERE . . . Tianaa is a proprietary blend of Natural Herbs and Nootropics created to deliver the unparalleled pick up, clarity, relaxation, and relief”\n\nYour “Tianaa Red,” “Tianaa White,” and “Tianaa Green” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S.\n\nCaptain, U.S Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration","Premier Manufacturing Products, LLC","premier-manufacturing-products-llc-678912-07022024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremier-manufacturing-products-llc-678912-07022024","2026-10-26T08:09:43.462221+00:00","2024-07-02","678912","James P. Morrissette","2026-08-20T00:00:07.13+00:00","Via Email Atofil@mtdst.us",{"id":249,"raw":250,"subject":12,"body_html":254,"body_text":255,"firm_name":256,"letter_id":257,"created_at":18,"fei_number":19,"letter_url":258,"updated_at":259,"action_type":22,"case_status":23,"posted_date":260,"marcs_cms_no":261,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":262,"body_fetched_at":263,"delivery_method":29,"recipient_title":19,"reference_number":264,"action_taken_date":265,"medical_device_id":19,"response_letter_date":19},183,[251,252,253,11,12,13,13,13],"\u003Ctime datetime=\"2026-05-05T04:00:00Z\">05\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-22T04:00:00Z\">04\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Factive-cosmetics-manufacturing-inc-722408-04222026\">Active Cosmetics Manufacturing Inc. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-71\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Celia Ferreira\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Active Cosmetics Manufacturing Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7075 Kingspointe Parkway, Suites 2, 3, 4, and 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Orlando\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32819-6540\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-71\u003C\u002Fp>\u003Cp>April 22, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Ferreira:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Active Cosmetics Manufacturing Inc., FEI 3005351079, at 7075 Kingspointe Parkway, Suites 2, 3, 4, and 5, Orlando, from October 27 to 31, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 21, 2025 response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture topical over-the-counter (OTC) drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> labeled for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You failed to adequately investigate out-of-specification (OOS) microbiological test results of your drug products.\u003C\u002Fp>\u003Cp>You released batches for commercial distribution based on passing retest results, without conducting thorough investigations to determine the root causes of the original results. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> was found to contain the objectionable microorganism \u003Cem>Staphylococcus aureus\u003C\u002Fem>.\u003C\u002Fli>\u003Cli>Batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> was found to contain the objectionable microorganism \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem>.\u003C\u002Fli>\u003Cli>Batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed the Neogen Soleris Next Generation System test that you claimed assesses total viable count.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Passing retest results alone cannot serve as the basis for invalidating OOS results. As a manufacturer, you have a responsibility to fully investigate aberrant microbial test results that may impact drug product quality. In addition, investigations into microbial contamination should include awareness that microbial contamination is not uniformly distributed.\u003C\u002Fp>\u003Cp>These findings are indicative of a lack of state of control of your manufacturing processes. We note that your firm has not performed process validation studies to determine whether the processes used to produce your marketed OTC drugs are reliable and reproducible.\u003C\u002Fp>\u003Cp>In your response, you state you retested reserve samples from affected batches and initiated an investigation. You also revised your OOS procedure to include more detailed guidance on phase I and II investigations, root cause determination, and to assess impact on other batches and procedures.\u003C\u002Fp>\u003Cp>Your response is inadequate because it lacks a systemic investigation into the root cause of the OOS microbial results. Additionally, your response lacks a comprehensive drug product impact assessment that accounts for potentially impacted drug products within expiry.\u003C\u002Fp>\u003Cp>It is essential to conduct thorough, well documented, and scientifically sound investigations to identify root causes of OOS results, evaluate all potentially affected batches, and implement timely and effective corrective action and preventive action (CAPA) plans.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing PPQ for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocols, and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately validate your alternative rapid microbiological test methods. You use the Neogen Soleris Next Generation System for rapid microbiological testing of your finished drug products (e.g., total aerobic counts, total counts, specified microorganisms) and failed to demonstrate that it was equivalent to or better than United States Pharmacopeia (USP) compendial methods and suitable for its intended use.\u003C\u002Fp>\u003Cp>You stated that this system was validated by the manufacturer. However, your method did not meet the minimum requirements for adequate identification of objectionable microorganisms and total count quantification.\u003C\u002Fp>\u003Cp>The microbiological testing methodology uses qualitative pass\u002Ffail criteria that do not ensure appropriate quantitative enumeration. The method is inadequate because it does not provide sufficient data on contamination levels, which are essential for trend analysis and evidence-based risk assessment to support quality evaluations and patient safety.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that you have not validated your alternative rapid microbiological test methods. You state you will fully validate methods used in your alternative rapid microbiological testing within six to eight months.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to address the fundamental gap between qualitative pass\u002Ffail criteria and appropriate quantitative enumeration.\u003C\u002Fp>\u003Cp>Test methods must be validated to show that they are suitable for their intended use and equivalent to or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine whether your drug products meet established specifications for microbial attributes.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A comprehensive independent evaluation of microbiological tests methods used to perform total counts and identification to evaluate suitability for intended use, followed by systemic CAPA including, but not limited to:\u003Cbr>o A comprehensive retrospective evaluation of each test method to determine any inadequacies including, but not limited to, those cited in this letter.\u003Cbr>o Where a method is found unsuitable for its intended use (e.g., inadequate capacity to accurately enumerate, microbial identification), provide information on a new suitable method that will be employed.\u003Cbr>o Improved systems to ensure suitability of microbiological test methods in the future before implementation.\u003Cbr>o Once this full evaluation is complete, provide a summary of findings, data, and all deviations encountered.\u003C\u002Fli>\u003Cli>Following review by an independent third-party, provide updated validation protocols and final reports that adequately address methods for each product, including specificity, limit of detection, robustness, ruggedness, and repeatability. This should also include an evaluation of whether sample sizes are appropriate. Where you intend to use non-compendial methods, provide studies evaluating the equivalence or superiority of the method to the USP method.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed in the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to perform adequate identity testing on each shipment of each lot of incoming components (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) used in the manufacture of your drug products. In addition, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of each of your component suppliers’ analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately test each shipment of each lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which you used as inactive ingredients in your drug products, for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. Complete identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain other high-risk drug components includes a limit test in the USP to ensure that the component meets the relevant safety limits for levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your response, you state that you have conducted a retrospective analysis and intend to have a qualified independent laboratory perform additional analysis. However, you fail to show that the retrospective testing meets full USP compendial requirements for ingredients at high risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. You also fail to show that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> you tested from your current inventory are fully representative of the component lots you used in your drug products that remain within expiry.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have assurance that components conform to appropriate specifications prior to use in the drug products you manufacture. As a manufacturer, you have the responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data)\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systemic CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>After you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005351079 and ATTN: Rokhsana Safaai-Jazi.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nReference #:\n\n320-26-71\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Celia Ferreira\n\nRecipient Title\n\nCEO\n\nActive Cosmetics Manufacturing Inc.\n\n7075 Kingspointe Parkway, Suites 2, 3, 4, and 5\n\nOrlando, FL 32819-6540\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-71\nApril 22, 2026\nDear Ms. Ferreira:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Active Cosmetics Manufacturing Inc., FEI 3005351079, at 7075 Kingspointe Parkway, Suites 2, 3, 4, and 5, Orlando, from October 27 to 31, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 21, 2025 response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYou manufacture topical over-the-counter (OTC) drug products, including (b)(4) labeled for use in (b)(4). You failed to adequately investigate out-of-specification (OOS) microbiological test results of your drug products.\nYou released batches for commercial distribution based on passing retest results, without conducting thorough investigations to determine the root causes of the original results. For example:\nBatch (b)(4) was found to contain the objectionable microorganism Staphylococcus aureus.\nBatch (b)(4) was found to contain the objectionable microorganism Pseudomonas aeruginosa.\nBatch (b)(4) failed the Neogen Soleris Next Generation System test that you claimed assesses total viable count.\nPassing retest results alone cannot serve as the basis for invalidating OOS results. As a manufacturer, you have a responsibility to fully investigate aberrant microbial test results that may impact drug product quality. In addition, investigations into microbial contamination should include awareness that microbial contamination is not uniformly distributed.\nThese findings are indicative of a lack of state of control of your manufacturing processes. We note that your firm has not performed process validation studies to determine whether the processes used to produce your marketed OTC drugs are reliable and reproducible.\nIn your response, you state you retested reserve samples from affected batches and initiated an investigation. You also revised your OOS procedure to include more detailed guidance on phase I and II investigations, root cause determination, and to assess impact on other batches and procedures.\nYour response is inadequate because it lacks a systemic investigation into the root cause of the OOS microbial results. Additionally, your response lacks a comprehensive drug product impact assessment that accounts for potentially impacted drug products within expiry.\nIt is essential to conduct thorough, well documented, and scientifically sound investigations to identify root causes of OOS results, evaluate all potentially affected batches, and implement timely and effective corrective action and preventive action (CAPA) plans.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequate scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing PPQ for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocols, and written procedures for qualification of equipment and facilities.\n2. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\nYou failed to adequately validate your alternative rapid microbiological test methods. You use the Neogen Soleris Next Generation System for rapid microbiological testing of your finished drug products (e.g., total aerobic counts, total counts, specified microorganisms) and failed to demonstrate that it was equivalent to or better than United States Pharmacopeia (USP) compendial methods and suitable for its intended use.\nYou stated that this system was validated by the manufacturer. However, your method did not meet the minimum requirements for adequate identification of objectionable microorganisms and total count quantification.\nThe microbiological testing methodology uses qualitative pass\u002Ffail criteria that do not ensure appropriate quantitative enumeration. The method is inadequate because it does not provide sufficient data on contamination levels, which are essential for trend analysis and evidence-based risk assessment to support quality evaluations and patient safety.\nIn your response, you acknowledge that you have not validated your alternative rapid microbiological test methods. You state you will fully validate methods used in your alternative rapid microbiological testing within six to eight months.\nYour response is inadequate because it fails to address the fundamental gap between qualitative pass\u002Ffail criteria and appropriate quantitative enumeration.\nTest methods must be validated to show that they are suitable for their intended use and equivalent to or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine whether your drug products meet established specifications for microbial attributes.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA comprehensive independent evaluation of microbiological tests methods used to perform total counts and identification to evaluate suitability for intended use, followed by systemic CAPA including, but not limited to:\no A comprehensive retrospective evaluation of each test method to determine any inadequacies including, but not limited to, those cited in this letter.\no Where a method is found unsuitable for its intended use (e.g., inadequate capacity to accurately enumerate, microbial identification), provide information on a new suitable method that will be employed.\no Improved systems to ensure suitability of microbiological test methods in the future before implementation.\no Once this full evaluation is complete, provide a summary of findings, data, and all deviations encountered.\nFollowing review by an independent third-party, provide updated validation protocols and final reports that adequately address methods for each product, including specificity, limit of detection, robustness, ruggedness, and repeatability. This should also include an evaluation of whether sample sizes are appropriate. Where you intend to use non-compendial methods, provide studies evaluating the equivalence or superiority of the method to the USP method.\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed in the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou failed to perform adequate identity testing on each shipment of each lot of incoming components (e.g., (b)(4)) used in the manufacture of your drug products. In addition, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of each of your component suppliers’ analyses at appropriate intervals.\n(b)(4)\nYou failed to adequately test each shipment of each lot of (b)(4), which you used as inactive ingredients in your drug products, for (b)(4) contamination. Complete identity testing for (b)(4), and certain other high-risk drug components includes a limit test in the USP to ensure that the component meets the relevant safety limits for levels of (b)(4). Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for (b)(4) contamination at (b)(4).\nIn your response, you state that you have conducted a retrospective analysis and intend to have a qualified independent laboratory perform additional analysis. However, you fail to show that the retrospective testing meets full USP compendial requirements for ingredients at high risk for (b)(4) contamination. You also fail to show that the (b)(4) you tested from your current inventory are fully representative of the component lots you used in your drug products that remain within expiry.\nWithout adequate testing, you do not have assurance that components conform to appropriate specifications prior to use in the drug products you manufacture. As a manufacturer, you have the responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine whether they are consistently of acceptable quality\no a review to ensure assigned expiration or retest dates are appropriate (supported by data)\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\nBased on a thorough review, provide a summary of your systemic CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\nA commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nAfter you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005351079 and ATTN: Rokhsana Safaai-Jazi.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Active Cosmetics Manufacturing Inc.","active-cosmetics-manufacturing-inc-722408-04222026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Factive-cosmetics-manufacturing-inc-722408-04222026","2026-10-26T08:07:49.865485+00:00","2026-05-05","722408","Ms. Celia Ferreira","2026-08-19T04:43:26.19+00:00","320-26-71","2026-04-22",{"id":267,"raw":268,"subject":12,"body_html":271,"body_text":272,"firm_name":273,"letter_id":274,"created_at":86,"fei_number":19,"letter_url":275,"updated_at":276,"action_type":22,"case_status":23,"posted_date":114,"marcs_cms_no":277,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":278,"body_fetched_at":279,"delivery_method":191,"recipient_title":19,"reference_number":280,"action_taken_date":281,"medical_device_id":19,"response_letter_date":19},628,[100,269,270,11,12,13,13,13],"\u003Ctime datetime=\"2025-09-11T04:00:00Z\">09\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcolumbia-cosmetics-manufacturing-inc-710885-09112025\">Columbia Cosmetics Manufacturing Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-108\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Rachel Rendel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder\u002FOwner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Columbia Cosmetics Manufacturing Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1661 Timothy Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Leandro\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94577-2311\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-108\u003C\u002Fp>\u003Cp>September 11, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Rendel:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Columbia Cosmetics Manufacturing Inc, FEI 2919184, at 1661 Timothy Dr., San Leandro, CA, from April 7 to 14, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your May 2, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture over-the-counter (OTC) sunscreen drug products. Your firm failed to conduct adequate investigations into out-of-specification (OOS) results. For example, an OOS result for bulk batch \u003Cstrong>(b)(4) \u003C\u002Fstrong>indicated subpotency for one of the active pharmaceutical ingredients (APIs). The corrective action was to reprocess the drug product by adding additional API. The subsequent finished drug product retesting showed that this batch remained subpotent.\u003C\u002Fp>\u003Cp>Furthermore, this reprocessing was performed without the review and approval of your Quality Unit (QU). Your QU released failing drug product without an investigation regarding the finding of subpotent finished product.\u003C\u002Fp>\u003Cp>You did not thoroughly investigate these unexplained discrepancies or identify failures in a drug product to meet any of its specifications. An investigation into the failure of bulk product was initiated only after drug product was released. This investigation was inadequate in that its conclusion, API “evaporation,” was not scientifically supported. Additionally, this investigation failed to address the improper release of subpotent finished product, implement appropriate corrective action and preventive action (CAPA), and expand the investigation to evaluate the impact on other batches of drug products.\u003C\u002Fp>\u003Cp>In your response, you revise your standard operating procedure (SOP) to require investigation of OOS results by your QU. Your response also attempts to invalidate the OOS of finished drug product. Your response is inadequate. Without adequate scientific justification, you claim the test method associated with the OOS is not suitable. Additionally, you fail to extend your investigation to other batches impacted by this method. Therefore, your investigation fails to identify a sufficiently supported root cause or implement appropriate corrective actions. Moreover, your response does not propose to perform any retrospective impact assessment of previously distributed drug products or to re-evaluate the adequacy of any previously invalidated OOS results. As a manufacturer, you have a responsibility to fully investigate unexplained discrepancies and failures to assess impact to drug product quality.\u003C\u002Fp>\u003Cp>For more information about handling failing, OOS, out-of-trend (OOT), or other unexpected results and documentation of your investigations, see FDA’s guidance document: \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\u003Cbr>o QU oversight of laboratory investigations.\u003Cbr>o Identification of adverse laboratory control trends.\u003Cbr>o Resolution of causes of laboratory variation.\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified.\u003Cbr>o Adequately scoping of each investigation and its CAPA.\u003Cbr>o Revised OOS investigation procedures with these and other remediations.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You did not perform adequate identity testing on each shipment of each lot of incoming components (e.g., glycerin) used in the manufacture of your OTC drug products. Additionally, you relied on your suppliers’ certificates of analysis (COAs) without establishing the reliability of each of your suppliers’ analyses at appropriate intervals (e.g., avobenzone).\u003C\u002Fp>\u003Cp>For example, you failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin to determine its appropriate identity.\u003C\u002Fp>\u003Cp>Identity testing for glycerin and certain other high-risk drug components include a limit test in the USP to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>In your response, you commit to performing testing for DEG and EG in glycerin and provide test results performed on retained component samples. Your response is inadequate in that it fails to consider other high-risk components used in your drug products, including but not limited to, propylene glycol. In addition, your response does not provide sufficient details on how you will establish the reliability of your component suppliers’ COAs at appropriate intervals.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High Risk Drug Components for Diethylene Glycol and Ethylene Glycol \u003C\u002Fem>to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPAs that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately validate your manufacturing processes to demonstrate that your processes are reproducible and controlled to consistently yield drug products of uniform character and quality. For example, your OTC drug products, Rejuva Mineral Daily Wear Face Protection Moisture SPF16 and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were manufactured without adequate validation of your manufacturing processes, including performance of process qualification studies.\u003C\u002Fp>\u003Cp>In your response, you state that you will perform a retrospective validation of the drug products that you manufactured using an unvalidated process. You also state that you will develop a procedure for prospective validation of reprocessed drug products.\u003C\u002Fp>\u003Cp>Your response is inadequate because you do not commit to ensuring prospective validation studies are completed prior to continued distribution of these drug products, nor do you include a risk assessment for marketed drug products manufactured by unvalidated processes. Moreover, it is unclear from your response how your proposed prospective validation of reprocessing will cover every potential reprocessing situation for all drug products manufactured at your facility.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem>, for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products. Also include an explanation how you will ensure proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Ineffective Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2919184 and ATTN: Andrew Haack.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-108\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Rachel Rendel\n\nRecipient Title\n\nFounder\u002FOwner\n\nColumbia Cosmetics Manufacturing Inc.\n\n1661 Timothy Dr.\n\nSan Leandro, CA 94577-2311\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-108\nSeptember 11, 2025\nDear Ms. Rendel:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Columbia Cosmetics Manufacturing Inc, FEI 2919184, at 1661 Timothy Dr., San Leandro, CA, from April 7 to 14, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your May 2, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYou manufacture over-the-counter (OTC) sunscreen drug products. Your firm failed to conduct adequate investigations into out-of-specification (OOS) results. For example, an OOS result for bulk batch (b)(4) indicated subpotency for one of the active pharmaceutical ingredients (APIs). The corrective action was to reprocess the drug product by adding additional API. The subsequent finished drug product retesting showed that this batch remained subpotent.\nFurthermore, this reprocessing was performed without the review and approval of your Quality Unit (QU). Your QU released failing drug product without an investigation regarding the finding of subpotent finished product.\nYou did not thoroughly investigate these unexplained discrepancies or identify failures in a drug product to meet any of its specifications. An investigation into the failure of bulk product was initiated only after drug product was released. This investigation was inadequate in that its conclusion, API “evaporation,” was not scientifically supported. Additionally, this investigation failed to address the improper release of subpotent finished product, implement appropriate corrective action and preventive action (CAPA), and expand the investigation to evaluate the impact on other batches of drug products.\nIn your response, you revise your standard operating procedure (SOP) to require investigation of OOS results by your QU. Your response also attempts to invalidate the OOS of finished drug product. Your response is inadequate. Without adequate scientific justification, you claim the test method associated with the OOS is not suitable. Additionally, you fail to extend your investigation to other batches impacted by this method. Therefore, your investigation fails to identify a sufficiently supported root cause or implement appropriate corrective actions. Moreover, your response does not propose to perform any retrospective impact assessment of previously distributed drug products or to re-evaluate the adequacy of any previously invalidated OOS results. As a manufacturer, you have a responsibility to fully investigate unexplained discrepancies and failures to assess impact to drug product quality.\nFor more information about handling failing, OOS, out-of-trend (OOT), or other unexpected results and documentation of your investigations, see FDA’s guidance document: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\nIn response to this letter, provide:\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\no QU oversight of laboratory investigations.\no Identification of adverse laboratory control trends.\no Resolution of causes of laboratory variation.\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified.\no Adequately scoping of each investigation and its CAPA.\no Revised OOS investigation procedures with these and other remediations.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou did not perform adequate identity testing on each shipment of each lot of incoming components (e.g., glycerin) used in the manufacture of your OTC drug products. Additionally, you relied on your suppliers’ certificates of analysis (COAs) without establishing the reliability of each of your suppliers’ analyses at appropriate intervals (e.g., avobenzone).\nFor example, you failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin to determine its appropriate identity.\nIdentity testing for glycerin and certain other high-risk drug components include a limit test in the USP to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nIn your response, you commit to performing testing for DEG and EG in glycerin and provide test results performed on retained component samples. Your response is inadequate in that it fails to consider other high-risk components used in your drug products, including but not limited to, propylene glycol. In addition, your response does not provide sufficient details on how you will establish the reliability of your component suppliers’ COAs at appropriate intervals.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIn response to this letter, provide:\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPAs that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYou failed to adequately validate your manufacturing processes to demonstrate that your processes are reproducible and controlled to consistently yield drug products of uniform character and quality. For example, your OTC drug products, Rejuva Mineral Daily Wear Face Protection Moisture SPF16 and (b)(4), were manufactured without adequate validation of your manufacturing processes, including performance of process qualification studies.\nIn your response, you state that you will perform a retrospective validation of the drug products that you manufactured using an unvalidated process. You also state that you will develop a procedure for prospective validation of reprocessed drug products.\nYour response is inadequate because you do not commit to ensuring prospective validation studies are completed prior to continued distribution of these drug products, nor do you include a risk assessment for marketed drug products manufactured by unvalidated processes. Moreover, it is unclear from your response how your proposed prospective validation of reprocessing will cover every potential reprocessing situation for all drug products manufactured at your facility.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance for industry, Process Validation: General Principles and Practices, for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate PPQ for each of your marketed drug products. Also include an explanation how you will ensure proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nIneffective Quality Systems\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2919184 and ATTN: Andrew Haack.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Columbia Cosmetics Manufacturing Inc.","columbia-cosmetics-manufacturing-inc-710885-09112025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcolumbia-cosmetics-manufacturing-inc-710885-09112025","2026-10-26T08:08:17.0728+00:00","710885","Ms. Rachel Rendel","2026-08-19T16:19:47.809+00:00","320-25-108","2025-09-11",14,{"510k":284,"classification":285,"enforcement":286,"event":287,"event_backfill":288,"pma":289,"warning_letter":290},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]